The Role of bFGF, IGF-I, PDGF and TGF-ß in the Expression of the Osteogenic Phenotype in Human Marrow-Derived Bone-Like Cells In Culture by Stobbe, David
 - 1 - 
Aus der Chirurgischen Klinik und Poliklinik der Innenstadt  
der Ludwig-Maximilians-Universität München  
Direktor: Professor Dr. W. Mutschler 
 
 The Role of 
bFGF, IGF-I, PDGF and TGF-ß in the Expression of 
the Osteogenic Phenotype in 
Human Marrow-Derived Bone-Like Cells In Culture 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Medizin 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
vorgelegt von 
David Stobbe 
aus 
Cornwall, Canada 
 
2008 
 
 
 
 
 
 
 - 2 - 
_____________________________________________________________________ 
 
Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
Berichterstatter: Prof. Dr. Wolf Muschler 
Mitberichterstatter: Prof. Dr. Christian P. Sommerhof 
Mitbetreuung durch den 
promovierten Mitarbeiter: P.D. Dr. Matthias Schieker 
Dekan: Prof. Dr. med. Dietrich Reinhardt 
Tag der mündlichen Prüfung:   08.05.2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 3 - 
 
 
Table of Contents                                                       
 
Page 
                           
1. Introduction           5  
 
1.1 Bone Development and Growth Factors       6 
 
1.2 Mesenchymal Stem Cells and Osteoblastic Development    7 
 
1.3 TGFß Superfamily and Bone Morphogenetic Proteins     9 
 
1.4 Growth Factors: bFGF, PDGF, and IGF      11 
   
1.5 In Vitro Cell Culture and Experimental Parameters               15 
 
1.6  Experimental Proposal                   
           20 
 
 
2. Materials and Methods         
 
2.1 Cells and Culture Conditions        21 
              
2.2. Organization of Groups        21 
             
 
2.3. Measurement of Parameters Characteristic of Osteoblastic Phenotype:   22 
             
2.3.1 Physical Parameters : Cell Morphology, Cell Count, Bone Nodule  22 
  Formation          
2.3.2 Staining Procedures : von Kossa Stain for Calcium Content   24 
2.3.3 Biochemical Parameters : Osteocalcin, Collagen Type I   25   
 
 
3. Results           
 
3.1.  Physical Parameters:  
3.1.1. Cell Morphology          26 
3.1.3 Bone Nodule Formation        28 
 
3.2.  Staining Procedures : 
 3.2.1 von Kossa Stain for Calcium Content      30     
3.2.2  Photographic Record of Calcium Content      33 
 
3.3.  Biochemical Parameters :         
3.3.1 Osteocalcin            37 
 - 4 - 
3.3.2 Procollagen  I  Levels        41  
 
 
4 Discussion 
 
4.1 Insulin-Like Growth Factor I (IGF-I)       45 
 
4.2 Platelet-Derived Growth Factor (PDGF)       48 
 
4.3 Basic Fibrolast Growth Factor (bFGF)       50 
 
4.4 Transforming Growth Factor ß (TGF-ß)       53 
 
 
5. Review, Clinical Relevance and Future Directions  
 
5.1 Summary           57 
 
5.2 Clinical Relevance          58 
5.2.1 Strategies to Determine the Role of Growth Factors in   
Fracture Healing          58 
   
5.3 Cell Culture Considerations         59 
 
 
Literature             61 
Literatur (alphabetic)           71 
 
Anhang: Zusammenfassung in deutscher Sprache         81 
Summary (English)          82   
 Curriculum vitae (Lebenslauf)        83 
            
           
 
 
 
 
 
 
 
 
 
 
 
 
             
        
 - 5 - 
 
1. Introduction  
 
Of all structures in the human body which retain the capacity for growth and regeneration 
throughout post-foetal life, bone tissue possesses an additional potential for continuous 
internal remodelling and adaptation. To understand these complex physiological 
processes has been the drive behind research aimed at developing clinically effective 
methods of promoting repair of bony defects, especially in orthopaedic and plastic 
surgery. Although millions of fractures occur annually, and the majority heal 
satisfactorily, 5% to 10% result in delayed union or non-union. It is therefore a matter of 
ongoing importance to supplement and extend current management and prevention of 
these problems. It will be the purpose of this paper to present an in vitro tissue model, 
and to address the significance of bone tissue research, its foundations and applications. 
Broadly, we have based the following inquiry on the same four “cornerstones” upon 
which all preceding research has been built. We assume: 
  
a) the dependence of bone healing on certain physiological proteins and growth factors,  
b) produced by bone cells themselves;  
c) the structure and relevance of a pre-clinical in vitro bone-culture study, and  
d) the potential of practical treatment possibilities evolving in the field of tissue grafting, 
bone graft substitutes and bone tissue engineering 1.  
 
Purpose of the Study:  
  
Specifically, we considered the effects of four physiological proteins on the growth of 
bone tissue in vitro: transforming growth factor beta (TGF-ß), insulin-like growth factor I 
(IGF-I), basic fibroblast growth factor (bFGF) and  platelet-derived growth factor (PDGF), 
and compare these effects to an untreated control group. In what way, if any, do these 
proteins improve or inhibit bone growth and metabolism as indicated by objectively 
measured parameters?  
 
Extensive research in this field has already demonstrated that all of these factors can 
and do affect bone growth in an animal model, both in vitro and in vivo. A major area, 
largely unexplored however, is the characterization of these effects on human bone 
tissue. Using the same experimental parameters as those published in the literature, the 
goal of this project was to describe the patterns of growth and/or growth inhibition of 
each of these compounds on human bone cells. These can be summarized as follows: 
 
IGF-I is a stimulator of the osteoblastic phenotype, a temporal regulator of development 
and is capable of increasing cell survival in human mesenchymal stromal cells. 
 
 PDGF functions as an ‘early-response’ factor; it stimulates osteoprogenitor cells in 
human bone tissue to proliferate, but may not promote the differentiation to mature 
osteoblast 
 
bFGF does not significantly stimulate the osteoblastic phenotype, but may hold osteo-
progenitor cells in a “stem-state” for a protracted period. 
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TGF-ß exhibits a biphasic regulation of osteoblast development involving initial 
suppression of matrix formation and later relative stimulation of cell aggregates into 
mineralised nodules.  
 
1.1. Bone Development and Growth Factors 
 
       Despite its complex makeup of osteoblastic and osteoclastic cell lineages set in a 
matrix of collagen and non-collagen proteins, bone tissue maintains a dynamic state.  
Studies as early as 1969, most notably by Harris and Heaney4 demonstrated the 
skeleton's ability to regulate its own volume, shape and strength in response to external 
stimulation 5,6. Chronic mechanical stress, disuse or disease states can alter the balance 
between osteoclastic resorption and osteoblastic generation for bone catabolism and 
anabolism respectively, according to the body's current needs. In general, two 
mechanisms have been suggested for the maintenance of bone volume: 1) systemic 
regulation by calcium- and phosphate-regulating hormones, e.g. parathyroid hormone, 
vitamin D, calcitonin, insulin; and 2) local regulation via protein growth factors. Growth 
factors are proteins synthesized by osteoblasts and non-osteoblastic skeletal and 
marrow cells. They are believed to act as autocrine (osteoblast-derived) and paracrine 
(non-osteoblast-derived) regulators of osteoblast proliferation and matrix biosynthetic 
activity .7-10  
 
Research within the last 15 years has increasingly supported the thesis that growth 
factors (insulin-like growth factor, transforming growth factor ß, basic fibroblast growth 
factor, platelet-derived growth factor and bone morphogenetic proteins) are stored in the 
matrix and osteoid of skeletal tissue 11-13, and are released by the resorptive actions of 
osteoclasts. Baylink and Finkelman (1993)5 set up an evolving model to illustrate the 
local effects of growth factors on bone development (Fig.1-1 and 1-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1-1  Effects of growth factors on bone 
development-I: Growth factors released 
from osteoblast are either stored, or 
released to influence producer osteoblast 
and other cells. Taken from Baylink and 
Finkelman (1993) 5 
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According to this representation, growth factors are fixed for a time into the bone matrix 
by means of binding proteins specific for each of the respective factors. In the course of 
normal physiological utilization of bone calcium reservoir, osteoclastic resorption 
releases growth factors in a bioactive form to act on osteoblasts and pre-osteoblasts to 
induce a site-specific replacement of tissue lost to resorption. In this manner, formation 
and resorption are "coupled" to one another such that they are “proportional to one 
another, site specific, and mediated by an increase in the number of osteoblasts” 14-17. 
This model can be demonstrated in vivo by the systemic treatment of animals with 
agents that stimulate bone resorption18. Paradoxically, the animals exhibit not only an 
increase in the amount of bone tissue resorbed, but also an increase in bone formation; 
this represents a counter-regulatory mechanism to maintain bone volume at acceptable 
levels 14,16,19.  
 
1.2. Mesenchymal Stem Cells and Osteoblastic Develo pment 
 
In order to more completely understand the effects of growth factors, it is necessary to 
look briefly at the origins and developmental stages of osteogenic cells, specifically 
osteoblasts. The formation and repair of bone tissue begins in the marrow, and involves 
undifferentiated cellular components that have been partly isolated and identified. It 
should be mentioned at the outset, however, that much research needs to be done 
before the precise nature of osteogenesis can be elucidated. 
 
Bone marrow consists of haematopoietic, endothelial and stromal elements, whose 
network of cells and matrix supply the necessary physical and chemical framework for 
new bone formation. The stromal cell population can be further subdivided into its 
individual components: fibroblasts, reticulocytes, muscle cells, adipocytes and 
osteogenic cells, also known as mesenchymal cells 24,25. These cell lines are believed to 
originate from a common progenitor, called (skeletal) mesenchymal stem cell (MSC) 20-
22,26-28, which are defined as the connective tissue elements providing structural and 
functional support for haematopoesis26. Cells of this group are undifferentiated and 
thought to possess fibroblastic, adipogenic, chondrogenic or osteogenic potential; 
however, the precise mechanisms that determine the subsequent course of development 
have not been established in every case. In general, osteoclasts seem  to be derived 
from macrophages and monocytes of the hemopoeitic system32,33,  while osteoblasts 
stem from the stromal system30,31; pioneer work by Friedenstein29 and Owen23 was 
refined by Long (1995)30, who isolated and characterized human bone precursor cells 
 
Fig 1-2  Effects of growth factors on bone 
development- II: Osteoclast resorption 
releases growth factors (GF) which 
stimulate preosteoblasts. Taken from 
Baylink and Finkelman (1993) 5   
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from nonadherent marrow cells. According to this study, isolated bone precursors are of 
three types: osteoprogenitor cells, preosteoblasts and osteoblast-like cells. Each of 
these subpopulations responds differently to exterior stimuli, osteogenic or otherwise, 
and so it becomes possible to „steer" the maturation of MSC's toward a given cell 
lineage (osteogenesis, chondrogenesis, adipocyte etc). Immunologically separated or 
embryonal pluripotent cell lines can be used to determine not only the physiological 
factors that commit an undifferentiated cell, but also the optimal time at which these 
factors must be present . Wang (1993)34, for example, induced embryonal mouse 
mesenchymal cells to differentiate into not only osteoblasts but also chondrocytes and 
adipocytes.  
 
A crucial question, then, in the field of in vitro bone research remains: What are the 
exogenous determinants of progenitor cell commitment? A model set up by Reddi (1995) 
illustrates the stages from precursor to osteocyte (Fig.1-3) 35. 
 
 
 
 
Based on the extensive study currently being done on growth factors and bone 
morphogenetic proteins (BMP's), Reddi proposed that certain of these proteins are 
stage-specific for MSC's commitment to a specific pathway: BMP's, for example are the 
primordial signal for the initial commitment of undifferentiated mesenchymal stem cells 
(also called inducible osteogenic precursor cells) to differentiated preosteoblasts 
(determined osteogenic precursor cells). The two subsequent steps, from preosteoblasts 
to osteoblasts and from osteoblasts to osteocytes are mediated by e.g. TGF-ß, and 
components of the extracellular matrix, respectively, leading to the formation of new 
bone 35. Inducible osteogenic precursor cells, i.e. MSC's, require a molecular signal for 
initiating the differentiation process, while determined cells i.e. post-preosteoblasts, will 
begin differentiating into bone even without an exogenous signal 35,36.  
 
 
 
1.3. TGFß Superfamily and Bone Morphogenetic Protei ns 
 
1.3.1 Cell Differentiation: Role of Bone Morphogenetic Proteins (BMPs) 
 
Any discussion of osteogenesis must include a short look at the role of bone 
morphogenic proteins and their effects on MSC and elsewhere.  Even though no BMP’s 
Fig. 1-3 Regulation of Bone Lineage by 
TGF-ß: Stages of cell development from 
precursor to osteocyte. Inducible 
precursor cells (MSC’s) become 
preosteoblasts and finally bone cells. 
Taken from Reddi (1995) 35. 
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were used in this project, they are mentioned for two reasons: 1) their importance to the 
regulation of bone lineage, and 2) the fact that information on BMP’s may help explain 
the characteristic effects of other growth factors, for example TGF-ß.  
 
The term BMP was first coined by Marshall Urist, MD, who in 1965 first reported 
extraskeletal osteoinduction 13, and has come to refer to any substance that can induce 
ectopic bone formation in a standard in vivo rodent assay 37. Roughly, BMPs are potent 
members of the multigene TGF-ß family; as little as 50 ng of purified extract is sufficient 
for in vivo activity 42. Within the marrow microenvironment, BMPs induce multi-potential 
stromal cells to differentiate along the osteoblastic pathway 2,38-40 (as summarized in Fig. 
1-3) and in doing so, blocks the development of MSC along other cell lineages, thereby 
functioning as negative regulator as well 21. Murray et al (1993) demonstrated for 
example that BMP will inhibit myotubule formation in committed C2C12 myoblasts in a 
concentration-dependent manner 41, and Gimble et al (1995) demonstrated the ability of 
BMP-2 to inhibit adipogenesis in mutipotential stromal cells 40. Gimble's model 
illustrating the actions and relationship of BMPs to the mesodermal cell lineages is 
summarized in Fig. 1-4. 
  
 
 
These considerations become important in view of the effects of TGF-ß on bone cell 
culture, discussed in Section 4.4. 
 
 
1.3.2 Cell Differentiation: Role of TGF-ß  
 
Having established the role of BMPs in the early commitment of inducible stromal cells, 
the next stage to be examined is the further differentiation of pre-osteoblasts once they 
are determined. As indicated in Fig. 1-3, the polypeptide TGF-ß, one of the most 
abundant of the known regulatory factors stored within the matrix 12, seems to be 
responsible for the stimulation of preosteoblast proliferation; this would serve to either 
create a large pool of committed cells, or alternatively to increase further differentiation 
of the osteoblasts themselves and thereby secretion of mineralising matrix proteins 11,47. 
Preliminary findings concerning the in vitro effects of TGF-ß have been variable: in some 
human osteoblast-like cells (osteoblastic osteosarcoma cells), TGF-ß has stimulated 
differentiated function and inhibited proliferation 48, while other researchers have seen 
stimulation of both differentiation and proliferation 165 in the same type of cells. This 
Fig. 1-4 Model of BMP regulation of 
mutipotential stromal cells along the 
mesodermal lineages. Taken from Gimble et al 
(1995) 40. 
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discrepancy may depend on the presence or absence of serum in in vitro cultures; TGF-
ß is stimulatory in the absence 39 but inhibitory in the presence 60 of serum. The 
proliferative effect of TGF-ß also appears to be dependant on maturity of the cells, (i.e. 
more proliferative on cells at an intermediate stage of bone development, less 
proliferative in cell cultures derived from mature organisms), and on concentration in 
culture (i.e. the stimulatory effect of TGF-ß on DNA synthesis decreases at high TGF-ß 
concentrations) 189. 
 
However, it seems clear that in populations of primary mammalian stem cells (in most 
studies taken from foetal rat calvaria), TGF-ß  
 
1) inhibits MSC differentiation to osteoblasts, while  
2) stimulating proliferation of the osteoblasts themselves 47,49,50. 
 
In other words, the major effects of TGF-ß on cell growth and differentiation are 
restricted to the proliferative phase of the culture, before osteoblasts express a mature 
phenotype. This leads to an initial suppression of “mature bone cell” characteristics, such 
as calcium deposition and nodule formation 50. However, continued exposure to TGF-ß 
leads cells to exhibit a second, positive growth response in the form of increased matrix 
formation and mineralization, i.e. a biphasic effect. These findings are further supported 
by studies implicating TGF-ß in the inhibition of osteoclast activity, i.e. osteoclasts are 
inhibited by TGF-ß from resorbing newly-formed ossic tissue 58,59. 
 
With regard to these inhibitory effects, accumulating evidence suggests that TGF-ß 
works closely in co-operation with 1,25 dihydroxyvitamin D3 (1,25(OH)2D3). This steroid 
hormone plays an important role in both calcium homeostasis and skeletal metabolism, 
and induces the transcription of major functional osteoblast products, such as 
osteocalcin and osteopontin. 1,25(OH)2D3 acts by coupling to distinct Vitamin D 
Response Elements (VDREs) located on the genetic promoter for osteocalcin synthesis; 
TGB-ß inhibition of osteoblast differentiation involves the selective down-regulation of 
Vitamin D interactions with osteocalcin VDREs 132,133. TFG-ß directly downregulates the 
expression of the osteocalcin gene in normal osteoblastic and osteosarcoma cells in rats 
159. 
 
 
1.3.3 TGF-ß and Osteoblast Recruitment 
 
Bone development occurs in a sequential cascade consisting of three steps: chemotaxis, 
mitosis and differentiation 35,50. Previous studies have suggested that an initial step in 
the coupling process during bone formation is likely to be a biochemical attraction of 
osteoblast-like cells to the site of previous resorption 51, which, interestingly, is another of 
TGF-ß's principle functions and has been demonstrated in rat and human osteoblasts; 
maximal stimulation of chemotaxis was observed at concentrations as low as 5-15 
pg/mL 51,166. Lind et al (1997) 166 studied the concentration-dependent stimulation of 
osteoblastic migration in response to TGF-ß, and noticed a decline in chemotactic 
response at higher doses. This phenomenon, also noticed in cells of the immunological 
system, seems to permit the pull of an osteogenic cell type from some distance away; 
migration is stopped when the cells are in the proper position and the higher 
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concentration of TGF-ß induces metabolic functions instead of migration 52,53. Lind 
formulates a hypothetical mechanism by which TGF-ß might exert its chemotactic 
influence: TGF-ß is released in an inactive form, bound to a binding protein to protect 
against initial hydrolytic cleavage. After release as an active protein, TGF-ß inhibits 
osteoclasts and enhances osteoblastic recruitment 54. Osteoblasts then migrate toward 
the resorption lacunae, where they are stimulated by TGF-ß together with other growth 
factors to proliferate and produce matrix proteins 55,166. This increase in matrix proteins is 
the second part of TGF-ß's biphasic influence; the variation, however, in culture model, 
dose ranges, delivery methods, protein isoform and end points for analysis make it 
difficult to establish these mechanisms in vitro as anything more than a rough guideline 
of TGF-ß´s possible effects. 
 
Structurally, TGF-ß belongs to a growing family of polypeptide factors, among them the 
activins, inhibins and BMPs, which share certain physical and functional characteristics. 
TGF-α is an unrelated peptide exhibiting a higher degree of homology with epidermal 
growth factor (EGF) than with the TGF superfamily.  Molecules producing TGF-ß have 
been observed in serum, blood platelets, chondrocytes and fibroblasts as well as 
extraskeletal locations such as placenta, kidney and astrocytes 56,57. There are an 
additional five isoforms of TGF-ß designated numerically TGF-ß1 through TGF-ß5, 
differing in receptor affinity and bioactive potency.  
 
 
1.4. Growth Factors: bFGF, PDGF, and IGF 
 
The distinction between the following growth factors and the TGF-ß superfamily is based 
for the most part on genetic composition; all such bioactive molecules exhibit 
overlapping functions and effects on the growth of skeletal tissue, and interact to varying 
degrees with one another within a physiological system. Thus the following description of 
the growth factors involved in this study will focus on their individual characteristics, 
keeping in mind their mutual influence on each other. 
 
1.4.1 Basic Fibroblast Growth Factor (bFGF) 
 
It is perhaps reasonable to discuss basic fibroblast growth factor immediately following 
TGF-ß because of the regulatory relationship between them; a study by Noda et al 
(1989) 61 reported an enhanced expression of TGF-ß genes in osteoblasts treated with 
bFGF. This discovery has been borne out in recent years in studies focussing on 
mesenchymal growth factors, which  include epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), and bFGF. Fibroblast growth factors are a group of 
polypeptides originally isolated from brain and pituitary extracts, and make up what is 
known as the heparin-binding growth factor (HBGF) family. Currently there are nine 
members which have been isolated in mammals; all are structurally related and are 
designated FGF-1 to FGF-9 66 . The following investigation deals only with a prototypic 
member, basic fibroblast growth factor (=FGF-2) because of its importance as a 
modulator of cartilage and bone growth and differentiation 26.  
 
Previous in vitro studies have ascribed various functions to bFGF, among them the 
stimulation of chondrocytes 67,68, osteoblasts 69,70, angiogenesis 78 and in regulation of 
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hematopoeisis 71. Both inducible marrow stromal cells and osteoblasts produce bFGF 62, 
and since bone matrix has been shown to contain this growth factor in abundance 12, it 
has been suggested that bFGF may preferentially trapped in the bone matrix with 
specific binding proteins in addition to being synthesized by bone cells. Canalis et al 
(1988) 70 determined the primary function of bFGF as being mitogenic; specifically, it 
reduces average cell replication time by shortening the G1-Phase of the mitotic cycle. 
These observations indicated that bFGF enhances osteogenesis by stimulating bone cell 
replication, which increases the number of collagen-synthesizing cells, but has a directly 
inhibitory effect on osteoblastic type-I collagen synthesis 70. In a study with periostium-
derived cells, all osteoblastic parameters i.e. osteocalcin and collagen gene expression, 
alkaline phosphatase (AP) activity and calcium content were decreased, whereas overall 
DNA content was enhanced. Iwasaki et al (1995) showed that bFGF is also a potent 
inhibitor of differentiation: MSCs in periostium were prevented from differentiating into 
either chondroblasts or osteoblasts, but were themselves induced to replicate 72. 
Especially important for the coupling between bone formation and resorption is 
consequently the inhibition by bFGF of osteoclast formation 62. These initial results 
indicate that in mesenchymal bone cell cultures, bFGF serves as a mitogenic factor for 
both differentiated and undifferentiated cells, but an inhibitor of cell lineage 
determination . 
 
In stromal marrow culture, however, several studies have noted that bFGF enhances 
proliferation and osteogenic expression of human marrow stromal cells 3,69,138. Treatment 
of culture with bFGF and glucocorticoids by Pri-Chen et al (1998) resulted in a four-fold 
increase in osteocalcin in addition to an overall DNA increase 134, which may reflect 
either bFGF stimulation of an expanded proportion of stromal osteogenic cells, or direct 
activation of the osteocalcin promoter gene. Martin et al (1997) established the tendency 
of bFGF to maintain MSC in a particular functional state, e.g. a stem state, and therefore 
to support growth and expansion of osteogenic precursors 138. These data are supported 
by in vivo studies that demonstrate increased levels of bFGF in developing (proliferating) 
chick limb buds; these levels then decline when differentiation begins 147. Taken 
together, these investigations suggest that bFGF may play a dual role in regulating 
osteogenic potential by:  
 
1) stimulating proliferation of committed and uncommitted progenitors in marrow 
MSC by maintenance in an embryological responsive state (stem state). The 
osteogenic potential of MSC is highly increased in the presence of bFGF, making 
conceivable the performance of autogenic bone reconstruction without the need 
for large amounts of bone marrow aspirate 138;  
 
2) reducing differentiation but increasing proliferation of periosteal (i.e. already 
committed) bone cells, which is necessary in the event of bone growth or fracture 
healing 72. 
 
 
Both of these functions are greatly dependant on dose and duration of treatment. 
 
 With regard to interactions with TGF-ß as mentioned above, bFGF has exhibited in 
several studies its ability to either counteract the effects of TGF-ß by downregulating the 
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number of TGF receptors in target cells 73, or to enhance TGF-ß effects by stimulating its 
gene expression in osteoblasts. This second responsibility would perhaps serve as a 
negative feedback mechanism against the inhibitory effects of bFGF. 
 
1.4.2 Platelet-Derived Growth Factor (PDGF) 
 
Early studies with platelet adhesion to damaged vascular intima demonstrated a 
significant local increase in smooth muscle cell and fibroblast proliferation, leading 
researchers to search for the source of this growth-promoting activity. The knowledge 
that cell-free, plasma-derived serum did not exhibit this activity, and that it could be 
restored by the reinfusion of platelets eventually led to the isolation of Platelet-Derived 
Growth Factor by Ross et al (1974)110. PDGF, like its counterparts, initiates a variety of 
biological responses in mesenchymal stem cells, which include proliferation, chemotaxis, 
and increased synthesis and degradation of extracellular matrix; it is especially 
expressed during osseous wound healing, is mitogenic and chemotactic for osteoblastic 
cells in vitro, and stimulates new bone formation in vivo 74-76. The effects of PDGF are in 
some ways quite similar to those of bFGF; Canalis et al (1989) demonstrated that PDGF 
is located in the matrix, stimulates DNA synthesis in rat marrow cultures and exhibits a 
strong mitogenic effect in, but is not specific for, osteoblast-like cells. In addition, PDGF 
may either inhibit the osteoblastic phenotype by decreasing AP activity, collagen 
synthesis and matrix apposition rates, or have no effect, for example on osteocalcin 
production. These effects could also be mediated in part by PDGFs inhibition of skeletal 
IGF, the most prevalent local stimulator of the differentiated function of osteoblasts 80. 
Generally, PDGF tends to increase replication but not differentiation 79. This  thesis is 
supported by Yu et al (1997) who found that continuous PDGF treatment increased 
histone expression, indicative of enhanced proliferation (replication) but suppressed 
differentiation as expressed by a decline in alkaline phosphatase, collagen and 
osteocalcin in rat calvarial cells 186. In contrast, Pfeilschifter et al (1992) reported the 
increase in collagen synthesis by 50% and a decrease in AP activity by 20% following 
treatment of rat calvarial cells with PDGF, suggesting that PDGF may have varying 
production patterns and effects in vivo  depending on the developmental stage of cells 
affected 55, i.e. a strong dependence on temporal factors. In contrast to bFGF, however, 
PDGF stimulates bone resorption by significantly increasing osteoclast number 81 and 
collagen degradation, possibly due to an elevation in collagenase levels 77,164. Consistent 
with the above characteristics is the finding that PDGF stimulates A- and B-chain mRNA 
production, an effect which is not specific to bones but also occurs in vascular 
endothelium 82.  
 
Structurally, PDGF exists as the product of two genes that encode two distinct chains, 
PDGF-A and PDGF-B. These chains share 60% amino acid homology and can combine 
to form a covalently-linked homo- or heterodimer comprising either A or B subunits i.e. 
PDFG-AA, -BB, or AB. This study employs one of these three isoforms, PDGF-BB, 
which  predominates in circulation and is the most potent in vitro at equivalent doses 
74,79; PDGF-BB, but not –AA, stimulates bone resorption and interstitial collagenase 
expression in osteoblasts 63. These effects seem to be dependent on the affinity of 
PDGF-BB for PDGF-receptor types α and β while PDGF-AA occupies only the α-
receptor. In fact, most, but not all, differences in isoform potency are due to different 
binding affinities for receptor subtypes 74.  
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PDGF synthesis takes place in stromal cells, macrophages and of course in platelets, 
and is stored in matrix; Rydziel et al (1996) 63 demonstrated PDGF-BB transcripts in 
normal osteoblasts, identifying it as a systemic and local regulator of bone cell function.  
 
1.4.3 Insulin-Like Growth Factor (IGF) 
 
Insulin-like growth factor, also known as somatomedin C (Sm-C), is a growth-hormone 
(GH)-dependent polypeptide synthesized primary in visceral organs, neural tissue and 
skeletal cells. It acts as both a systemic and local modulator of skeletal growth, and 
systemic agents; particularly parathyroid hormone and steroid hormones like estradiol 
have been shown to regulate the production and secretion of IGF in cells of the 
osteoblast lineage 80,87,88. Human serum contains several IGFs: the two major forms 
IGF-I and IGF-II plus several minor-sequence variants which comprise less than 10% of 
total physiological insulin-like activity in the human body. IGF-I and –II are single-chain 
polypeptides consisting of four domains, the first two of which (A and B) bear up to 43% 
sequence homology with the A and B domains of human proinsulin. Sequence homology 
between IGF-I and –II is 62%, but their effects and their respective active concentrations 
differ on several points. We chose to study IGF-I because of the high doses of IGF-II 
necessary to cause a relatively small stimulation of bone matrix production 187. The 
following discussion will therefore focus exclusively on the subject of this particular 
study, IGF-I.  
 
In terms of its effects, IGF-I operates in an autocrine/paracrine manner, regulating the 
proliferative and differentiative functions of bone cells 5,86. Unlike bFGF and PDGF 
described previously, IGF-I has been shown to stimulate proliferation and matrix 
synthesis in vitro, i.e. it increases the replication of cells of the osteoblastic lineage 
(probably preosteoblasts) and enhances osteoblastic collagen synthesis and matrix 
apposition rates and thereby the expression of proteins like alkaline phosphatase and 
osteocalcin 55,89 . This effect seems to be due to at least two regulatory signals: firstly, its 
direct influence on differentiated osteoblasts (enhancement of type I collagen production) 
and secondly, an increase in osteoprogenitor cell replication, giving a larger number of 
functional osteoblasts; these effects can be dissociated from each other biochemically, 
suggesting independent mechanisms 90. Insulin, by comparison, also stimulates collagen 
synthesis and matrix production but does not alter cell replication 91. Like many other 
local factors, IGF-I acts on both bone formation and resorption: first Mochizuki (1992) 
and more recently Hill et al (1995) 92,93 demonstrated that IGF-I stimulates bone 
resorption in vitro by enhancing both osteoclast formation (hemopoeitic recruitment) and 
activity. Interestingly, cells of the osteoblastic lineage mediated these effects; 
osteoclasts isolated from rat long bones did not respond to IGF-I if incubated alone. Only 
following the addition of osteoblastic derivatives of human osteosarcoma cells did the 
osteoclasts respond, suggesting that osteoblasts release a soluble factor to stimulate 
bone resorption 92,94 as outlined in Section 1.1. 
 
The question concerning IGF-I’s effects as a catabolic or anabolic agent becomes more 
significant in light of the in vivo action of IGF-I on mature, as opposed to growing, bone. 
IGF-I delivered by osmotic pump to osteoporotic rats increased bone formation rate and 
trabecular number; no such effect was noted in animals that did not have osteoporosis 
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184. Generally, current research shows IGF-I to stimulate mRNA expression of AP, 
procollagen, osteocalcin and osteopontin, but its in vitro effects on stromal cells appear 
to be age-related; older adult animals are more significantly affected than younger 
adults185.  
 
 
1.5. In Vitro Cell Culture and Experimental Parameters 
 
Up to this point, we have been using information regarding the actions of certain 
physiological growth factors obtained, for the most part, through the cultivation and 
examination of tissue cultures in an artificial environment, i.e. the long-term in vitro 
growth and maintenance of mammalian bone cells, human and otherwise. Tissue culture 
represents the main experimental ex vivo methodology by which researchers have 
established the osteochondral potential of MSC in bone marrow; subsequent stages 
leading toward animal (and eventually human) in vivo trials have typically involved bone 
and cartilage development in rat diffusion chambers, i.e. porous tricalcium phosphate-
hydroxyapatite ceramic cubes containing marrow-derived cells, implanted 
subcutaneously into syngeneic or immunocompromised hosts 100,101. An important 
question that must therefore be addressed is whether or not cell cultures can be utilized 
as accurate representation of a mammalian system, and by extension: Can the data 
extrapolated from an in vitro experiment be applied to an animal and eventually a human 
model?  
 
In vitro systems cannot entirely imitate an in situ microenvironment, and yet they provide 
useful models with which to study some, but not all aspects of osteoblast function. 
Techniques and conditions that isolate MSC in culture have been developed for avian 
102, rodent 103 and canine 104 models, leading to the extensive cultivation, subcultivation 
and characterization of human stromal cells 105-107.  Essentially, in vitro experiments in 
which stromal cells are induced to form bone fall into two broad categories: one in which 
the culture medium is supplemented with a phosphate donor (beta glycerophosphate, ß-
GP) and/or a steroid (dexamethasone, dex), and a second in which the medium is 
supplemented with an „inductive" peptide purified from demineralized bone matrix 
(DBM), for example one of the bone morphogenic proteins 108.  
 
Bone cells, as described previously, undergo a consistent in vitro developmental 
sequence (proliferation, matrix maturation and mineralisation) whose parameters can be 
regulated by the administration of bioactive signals 85. In addition, the temporal 
expression of bone matrix proteins during de novo bone formation in vivo has revealed 
distinct patterns for individual proteins 109,110. These same patterns of expression are 
seen during bone formation in vitro, allowing inferences to be made between the 
appearances of certain proteins, and e.g. cell differentiation stage 111,112. Such protein 
level parameters have become the most accurate available measure of osteoblastic 
function in research with bone cultures, as osteoblasts consistently exhibit a series of 
characteristics that have proven useful in their identification: alkaline phosphatase 
activity, increased intracellular cAMP in response to parathyroid hormone, the ability to 
form nodules with a mineralised extra cellular matrix comprised of type I collagen, and 
increased levels of the bone-specific proteins osteopontin, osteonectin, bone sialoprotein 
(BSP) and bone Gla protein (osteocalcin) 106. While all can be used as valid  parameters 
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to (indirectly) quantify the presence of osteoblasts in culture, only a select few, for 
reasons outlined below, were employed in the present study.  
 
1.5.1 Bone Marker Proteins  
 
Osteocalcin, the most abundant non-collagenous protein (about 15%), is one of the most 
reliable markers of bone tissue 113,114, and growing data indicates that it is the most 
specific to date for the osteoblast phenotype 120. It contains three residues of the 
calcium-binding amino acid (-carboxyglutamic acid (GLA), synthesized by a vitamin K-
dependent carboxylation of specific residues in a peptide chain; some authors consider it 
to be unique to osteoblasts / odontoblasts or tumour cells with osteoblastic potential 
126,128. Although originally thought to be involved in mineralization, the generation by 
Ducy et al (1996) 116 of mice lacking an osteocalcin gene showed that osteocalcin is a 
negative regulator of bone formation: the so-called 'osteocalcin-knockout mice' exhibited 
increased cortical thickness of the long bones but no concomitant  increase in the 
number of osteoblasts. Interestingly, the content and rate of apposition of bone minerals 
were identical between wild-type and mutant mice, suggesting that osteocalcin functions 
by limiting bone matrix resorption without affecting mineralisation 115,116. Osteocalcin, 
along with bone sialoprotein, is expressed after osteoblasts have differentiated (Fig.1-8) 
112; its  production has been identified with the committed step that includes matrix 
mineralisation.  
 
 
Collagen is the single most abundant animal protein in mammals, accounting for about 
30% of all proteins. Thirteen different types have been so far isolated in humans, 
designated types I-XIII; for the purposes of bone research, the most appropriate have 
proven to be types I and II. Collagen type I is not specific for bone but is also found 
abundantly in skin, tendon, ligament and cornea, where it comprises 80-90% of total 
collagen 118, nevertheless it is highly expressed by cells of connective tissue and the 
osteoblastic lineage, i.e. by the perichondrium, periosteum and osteoblasts 117,119. 
Significantly, Collagen I is directly associated with mineralization of bone nodules 
(described below), although some authors have not found a correlation between 
biochemical and histological determination of matrix apposition 55. Temporally, it is 
expressed during the period of cellular differentiation and matrix deposition (see Fig.1-8), 
and is synthesised as procollagen, a larger precursor molecule. Procollagen consists of 
mature collagen with extension peptides, which are cleaved from the collagen molecule 
by specific proteases prior to incorporation into a growing collagen fibril. The release of 
these peptides provides a stoichiometric representation of the production of collagen.   
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1.5.2 Non-Protein Parameters:   
 
Bone nodules 
 
  One of the most intriguing parameters of in vitro osteogenesis is the formation of 
colonies of differentiated osteoblasts and their associated matrix, called 'bone nodules'. 
These nodules comprise a multilayered system with an uppermost layer of cuboidal 
osteoblastic cells capable of producing an osteoid matrix similar to woven bone 120,121. 
Immediately beneath this 'osteoblast layer' is a seam of unmineralised matrix which can 
be seen with an electron microscope to contain collagen fibrils and exhibit the 
histological characteristics of osteoid. In addition, the matrix of mineralised nodules has 
been demonstrated to contain many of the components found in bone: collagen type I, III 
and V, osteonectin, osteocalcin and osteopontin. Based on these morphological and 
biochemical similarities, many researchers regard bone nodule structure as being very 
close to that of embryonic/woven bone synthesized in vivo 123-125.  
 
According to extensive work in this area by Bellows et al 122 the formation of nodules 
appears to be dependant on three distinct factors: the ability of cells to multilayer in vitro,  
the presence of ascorbic acid, and the addition of ß-glycerophosphate (ß-GP) to the 
culture medium. The ability to multilayer is important for the simple reason that cells 
respond to 'contact inhibition' if layering is not possible, and will not expand into a 3D 
structure when so hindered. Ascorbic acid seems to stimulate the formation and 
hydroxylation of collagen, allowing for the sufficient deposition of collagen to create a 
localized elevation in the culture surface. Finally, the mineralisation process requires an 
Fig. 1-5 . Taken from Li et al. (1996) 112,  the above diagram depicts the stages of 
osteoblast differentiation in fetal rat calvarial cells in vitro. Human marrow-derived 
culture and osteosarcoma cells exhibit similar characteristics 145,146 . 
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organic phosphate donor, and ß-GP, a substrate for AP, may contribute at least in part 
by providing this source of phosphate, even though it is not the same organic phosphate 
form found in vivo 126,127. 
 
Having briefly discussed the general conditions necessary to induce nodule 
development, the next phase involves an examination of the four successive 
morphological steps of bone nodule formation, elucidated by Nefussi et al (1997)183: 
  
cell proliferation with formation of multicellular layers – AP and non-collagen proteins 
(NCP) such as osteocalcin and osteopontin are not expressed until the creation of a 
three-dimensional microenvironment is completed; this may even include a transient 
cell-dedifferentiation state, to speed up proliferation during the first 24 hrs after 
plating.  
cell surface morphological changes with cell differentiation – the production of NCPs 
begins after 3D cell organization.   
cell activity with matrix formation and maturation – the cells, i.e. osteoblasts below the 
nodule surface, begin to actively synthesize matrix.   
woven bone matrix mineralisation – with formation of active bone surface and mature 
osteocytes.  The mineralisation of human MSC in culture is associated with an 
increase in calcium deposition in the extracellular matrix, especially calcium 
phosphate 120,135. 
 
These stages are not successive, but take place concomitantly at different locations 
during nodule development. 
 
 
 
The Role of Glucocorticoids in Bone Nodule Formation: 
 
It is important to note that a number of chemical elements are indispensable additions to 
medium if bone nodules are to develop at all:  glucocorticoids have been shown to be a 
prerequisite for the expression of osteogenic markers by stromal bone marrow cells 
derived from both animals and humans 134,135, possibly because of their ability to help 
recruit progenitors to the osteogenic lineage 134,136. Interestingly, some preliminary 
findings indicated that glucocorticoid, which induces the formation of nodules in animal 
bone-cell cultures, actually decreases nodule formation in human bone-derived cell 
cultures 123. Furthermore, Cheng et al (1994) 135 noted that unlike rodent and bovine 
marrow cultures, human MSC cultures in the presence of glucocorticoids only (no growth 
factors added) are unable to form any nodules at all, which may be partially explained by 
the tendency of glucocorticoid to induce the differentiation (recruitment) of 
osteoprogenitor cells while inhibiting their proliferation. This would also account for the 
well-documented inclination of long-term pharmacological doses of glucocorticoids to 
cause osteopenia in vivo: the inability of osteoprogenitor cells to properly multiply, as 
may occur during an intense regime of high-dose glucocorticoids, may lead to relatively 
diminished osteoblast numbers and bone loss 135,144. However it seems clear that for 
marrow cultures, physiological concentrations of glucocorticoids are necessary for both 
the differentiation of osteoprogenitor cells into cells that exhibit the osteoblastic 
phenotype, as well as mineralisation of the matrix synthesized by these cells. In addition, 
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glucocorticoids significantly affect bone-cell adhesion factors and the attachment of 
osteogenic cells to the extracellular matrix 137.  
 
Taken together, this information suggests that, on one hand, the in vitro induction of 
nodule formation in either bone-cell or bone marrow culture represents a valid and 
workable model for the study and understanding of in vivo bone characteristics. On the 
other hand, however, the dissimilar biochemical responses of animal versus human 
culture in the presence of glucocorticoids suggests that nodule-, and perhaps ultimately 
bone-formation and -mineralisation occur in two related yet comparable ways;  future 
growth factor research must include the more intense characterization of human cell 
populations. 
 
1.5.3 Serum Elements Necessary for Culture Growth  
 
Osteogenic Supplements 
 
One final element of nodule culture is the widely practised  augmentation of culture 
medium with two Osteogenic Supplements (OS): ß-glycerophosphate (ß-GP) and 
ascorbic acid (AsA).   
 
ß-Glycerophosphate (ß-GP): Even though the signals necessary for MSC to differentiate 
into various cell types are still not entirely understood, it has been proposed that ß-GP, in 
conjunction with AP, plays a significant role in promotion of both osteogenic 
differentiation and mineralisation in vitro, resulting in bone-like tissue formation 
108,120,139,140. ß-GP also appears to raise inorganic phosphate (Pi) and  depress AP levels 
in cell cultures 141, whereby concentration seems to be critical: Becerra et al (1996) 108 
reports that only concentrations below 2mM enhance physiological mineralization, 
whereas higher levels (up to 10mM) additionally stimulate increased calcium deposition. 
 
Ascorbic Acid:  AsA functions as a cofactor in the hydroxylation of proline and lysine 
residues in collagen 142, as well as increasing the synthesis of non-collagenous matrix 
proteins 143; it is generally considered as essential additive to osteogenic cell cultures 107. 
 
  
Proper Medium Selection 
 
The medium constituents play an important role in the eventual growth pattern and 
behaviour of cell cultures, especially marrow-derived MSC. Cell seeding density, type of 
tissue-culture plastic and source of foetal calf serum are known to affect the 
development  potential of cultured cells 100,107,142. Of special significance is the addition 
of foetal bovine serum, which contains many of the factors essential for in vitro 
proliferation: hormones; substrate-attachment molecules; binding proteins for the 
transport, presentation and utilization of essential molecules; and finally, nutrients which 
may be absent from synthetic medium or present in only insufficient concentrations. The 
following experiment makes use of a chemically defined medium (IMDM), augmentated 
with Horse Serum (HS) and Fetal Calf Serum (FCS) to permit attachment and 
proliferation of primary culture 24. 
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1.6.  Experimental Proposal 
 
The following experiment was established  to investigate the effects, whether positive or 
negative, of TGF-ß, IGF-I, bFGF and PDGF on osteoprogenitor cells. To do this, we set 
up an in vitro model using marrow stromal cells aspirated from the pelvic bones of adult 
human subjects. These cells were allowed to grow in an artificial, incubated environment 
for 7 days until a confluent layer of cells was visible, and were then continuously 
exposed to a single one of each the growth factors at a given concentration over a period 
of 24 days. To investigate dose dependency, two concentrations of each growth factor 
were used, 1 ng/mL and 10 ng/mL. A control group of cell culture from the same subject 
was grown under the same experimental conditions but without exposure to any growth 
factor. 
 
In order to measure the effect of these growth factors, we maintained a record of 
changes in parameters associated with maturation of in vitro bone cells as described in 
the literature. Visible cell morphology, cell count and matrix calcification (quantified by 
staining) were taken as indicators of culture activity and proliferation. Biochemical 
analysis for the bone proteins osteocalcin and procollagen, as well as development of 
bone nodules, were taken as indirect evidence of cell differentiation to the osteoblastic 
phenotype.  
 
An important part of the study was the observation of growth factor behaviour over an 
established time course; while many studies test growth factor activity as a statistical 
function of dose-dependence, very few authors, if any, show temporal passage. The 
experiment was planned so that all cultures in a given group were taken from the same 
subject (see Sec. 2.3), and enough sets were incubated at the beginning to allow for 
each to be analysed once and then discarded.  
 
The results thus acquired were analysed, interpreted and compared to findings reported 
by other research groups. 
 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and Methods         
 
2.1 Cells and Culture Conditions 
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Human mesenchymal stem cells (hMSC) were obtained from normal human donors 
(ages 20-30 years), via approximately 30-40 mL iliac crest aspiration. Isolation of MSC 
populations took place within 3-4 hours of operation; cells were separated from 
hematologic constituents of marrow aspirates by mixing with methyl cellulose (5mL) and 
Medium (∼25mL) in centrifuge tubes (Corning 50 mL) followed by removal and 
centrifugation of MSC at  700 x g and 4°C for 10 min. 
Supernatant pellet was resuspended in 10 mL medium; cell count to determine plating 
density was done with a 0,0025 mm2 hemacytometer (Neubauer, Germany). Cells were 
plated to a density not exceeding 1x106 cells/cm² on 4-well SonicSeal slide wells (Nunc, 
Illinois) and 24-well flat-bottom plates (Corning, MA).  
Plated cells, grown to confluence for 7 days before start of experiment, were kept 
incubated at 37° in a humidified atmosphere (Heraeus Instruments, Germany) consisting 
of  95% air and 5% CO2. Thereafter, culture medium was changed every 3 days for a 
total of 24 days.   
 
Medium: 
Iscove's Modified Dulbecco's Medium (IMDM) was supplemented with antibiotics 
(penicillin and streptomycin 1000 IU/mL), Foetal Calf Serum (10%), Horse Serum (10%), 
0.1 mL hydrocortisone stock and osteogenic supplements (10mM ß-glycerophosphate, 
ascorbic acid 50 g/mL) 
 
2.2.  Organization of Groups 
 
The present investigation concerns itself with the effect of growth factors on human 
marrow-derived MSC. The growth factors, as outlined in Sections 1.2 and 1.3 were 
divided up according to the following schema: 
 
GROUP 1 Marrow aspirate (35mL) from male patient, 22 yrs old.  
 
GROUP    FACTOR 1               FACTOR 2                 
1a                 IGF-1 1ng/mL    PDGF 1ng/mL    
1b           IGF-1 10ng/mL           PDGF 10ng/mL             Control  
 
Tab. 2-1 
 
GROUP 2 Marrow aspirate (35mL) from female patient, 28 yrs old. 
 
GROUP  FACTOR 3                FACTOR 4    
2a           bFGF 1ng/mL TGF-ß 1ng/mL    
2b           bFGF 10ng/mL TGF-ß 10ng/mL     Control  
 
Tab. 2-2 
 
Each group was cultured in duplicate, i.e. one set cultured in SonicSeal 4-well plates, 
and one set cultured in Corning 24-well flat-bottom plates (see Fig 2-1). The SonicSeal 
plates, which have a detachable plate and are therefore better suited for microscopic 
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examination, were used for cell morphology analysis, while the Corning plates were used 
for calcium staining procedures. 
 
Group n 
 
Set 1: SonicSeal culture       plastic well      
                 base 
Growth Factor 1                                      Growth  Factor 2 
 
 
 
 
 
1 ng/mL    10 ng/mL                    1 ng/mL       10ng/mL                   Control 
 
Set 2: Corning 24-well culture 
 
   Rows     1     2     3     4    5     6    Contents: Row 1:   Growth Factor 1 at 1ng/mL 
                                          Row 2:  Growth Factor 1 at 10ng/mL 
                                                               Row 3:  Growth Factor 2 at 1ng/mL 
                                                                        Row 4:  Growth Factor 2 at 10ng/mL 
 Row 5:  empty    
 Row 6:  Control (no Growth Factor 
added )  
 
 
Fig. 2-1 Organization of Groups. Each growth factor was added to 2 sets of culture (Sets 1 and 2) for 
duplicate measurements. Factors 3 and 4 were cultured in the same manner.   
                                           
After plating, cultures were left for one week to grow to confluence. The first day was 
then designated Day 7, marking the start of the 31-day experimental period. Medium was 
changed and photographic records made every three days i.e. Days 7, 10, 13, 16, 19, 
22, 25, 28 and 31 , allowing assessment of biochemical and morphological changes 
occurring within each 72-hr period.   
 
2.3.  Measurement of Parameters Characteristic of t he Osteoblastic Phenotype : 
   
2.3.1 Physical Parameters 
 
Cell Morphology 
 
Cells present in bone marrow culture, especially those such as fibroblasts and 
adipocytes visible at low light-microscope magnifications, assume identifiable patterns 
during their passage through various stages of growth. Individual cells were described as 
being spindle-shaped, cuboidal, polygonal (multifaceted) or filamentous, while patterns 
of aggregate cells were seen as whorls (i.e. broad spiral or whirled formation), islet-
formation (i.e. isolated islands of cells without definitive borders but with no contiguous 
abridgement to any other cell groups) or nodular (i.e. cell aggregates with a raised three-
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dimensional structure, or with a definite perimeter separating it from the surface layer). 
Furthermore, to characterize the spectrum of overall covering of the culture plate, cell 
layers were noted for their sparse, intermediate or confluent growth over the three-week 
period.  
  Documentation of cell morphology was done only in the SonicSeal cultures, using 
phase-contrast micrographs (Leitz, Germany) using Kodak Ektachrome 64T Colour 
Reversal Film, at magnifications of 1.2x, 4x, 10x, 20x and 32x. 
 
Cell Count 
 
Cell count was done with a hemacytometer (0.0025 mm², Neubauer, Germany) and light 
microscope (Leitz Diavert 40-100x magnification, Wetzlar, Germany). It reflects the 
absolute number of non-adherent cells free in medium. On every assessment day, (i.e. 
days 7,13,19, 25 and 31 ), 6mL from each group was set aside as a sample, centrifuged 
at 3 000 U/min and the supernatant removed. The pellet was resuspended in 1mL 
medium and stained in Tuerk solution at a ratio of 50µL medium to 50µL Tuerk's, after 
which 10µL was removed to the haemocytometer for counting. In the event that the cell 
concentration of a given day was not sufficiently high to allow adequate distinction 
between the groups, the ratio of medium to stain was altered to 90:10, respectively, and 
calculations made to accommodate this change. 
 
Bone nodules 
 
As discussed in Sec.1.4.2., bone nodule formation represents a measure of the bone 
culture's ability to form calcified structures similar to woven bone. For quantification of 
nodules, cell layers were stained in situ using the von Kossa technique (see Section 
2.4.2.), and nodules counted by placing plates under a light microscope at 4x 
magnification. Only those stained black by the von Kossa procedure were enumerated.  
 
 Formation of Adipocyte-Like Cells 
 
 As discussed in Sec 1.2 Mesenchymal Stem Cells, the pluripotent population of marrow 
precursors is thought to contain progenitors common to other cellular components of the 
body, among them adipocytes (Fig. 1-5). Given the assumption that our growth factors 
stimulate the osteoblastic phenotype, we observed the cultures for the degree to which 
other types of cell populations were either promoted or suppressed. The term 'adipocyte-
like' is used here to indicate that these cells were not characterized beyond their 
morphological appearance. 
 
 
 
 
 
 
2.3.2 Staining Procedures     
 
von Kossa Staining  
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For assessment of mineralization potential of bone cell culture, the plates were first 
drained of medium, then fixed with Histochoice Tissue Fixative (Sigma, MO) for 20 min. 
The cells were then washed with deionised water and exposed to 5% silver nitrate 
solution and UV light for 15 min. Following rinsing (de-ionised water) and addition of 1% 
Pyrogal solution, residual silver nitrate was neutralized with 5% thiosulphate.  Plates 
were assessed for the presence of stained areas, representing calcified nodules and 
surface area. An overall rating, assigned to each plate on days 7,13,19, 25 and 31  was 
based on an estimate of the percent surface area covered by stain (A). We assessed 
only those wells in which at least 75% of the well bottom was covered by  a cell layer. 
Further, each well was assigned a grade for depth of colour exhibited (B). Although 
there was some variability, a number of growth patterns were recognizable based on the 
following ranking: 
 
A= Percentage of layer stained:              B= Depth of colour 
       
Score   0= no stain observed  Score 0= stained area is transparent 
            1= 1-29%  of surface stained  1= stained area translucent, no colour 
             2= 30-59% of surface stained          2= translucent with opacity in < 50% of 
stained surface area 
3= 60-90% of surface stained  3= translucent with opacity in > 50% of 
stained surface area   
            
Table 2-3 Quantification of percentage of layer stained and depth of colour using objective score 
gradient. 
 
 
A final ranking was then given by plotting the score of percent layer stained (A) (Table 
2-3) and assigning a colour code to each histograph bar to signify depth of stain (B) 
(Table 2-4). This total score was then graphed to visualize both simultaneously. Results 
are shown in Section 3.3. 
 
Stain Intensity:            Score Attained in Table2-3 (B)       Colour Code 
        0………………….  
    1………………….         
                  2…………………. 
        3………………….  
 
Table 2-4: Quantification of depth of colour observed after staining using a colour gradient 
 
 
 
2.3.3.  Biochemical Parameters 
 
Osteocalcin (Gla-OC) 
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Median osteocalcin levels were measured by solid-phase enzyme immunoassay (Gla-
Type EIA-Kit, Lot No. 004, TaKaRa, Japan) according to the manufacturer’s instructions. 
This assays utilizes a set of mouse monoclonal antibodies (Mabs) to detect osteocalcin 
in both its carboxylated and decarboxylated forms. The procedure is a two-step 
'sandwich' method in which Gla-OC is bound to immobilized anti-Gla-OC (solid-phase on 
the bottom of the microtitre-plate well), and then tagged with peroxidase (POD)-anti-OC. 
A further reaction between POD and a chromogenic solution containing tetramethyl-
benzadine (TMB) results in colour development with intensity and absorbance 
proportional to the amount of Gla-OC present in the sample.  
Briefly, the procedure was done by incubating a medium sample (1:4) for 2 hours at 
room temperature (18-25°C) in a microtitre-plate we ll coated with anti-Gla-OC antibody. 
After aspirating the reagent from the well, the plate was washed three times, 
Chromogenic Solution added, and the plate incubated for a  further thirty minutes at 
room temperature on a horizontal shaker set at 700±100 rpm, avoiding direct sunlight. 
Afterward, Stop-Reagent was pipetted into the well and the absorbance read at 450 and 
490 nm.  
 
Type I Collagen  
 
Median levels of collagen in serum were measured using a solid-phase enzyme 
immunoassay (Prolagen-C® EIA-Kit, No. 8003, Metra Biosystems, California U.S.A) 
according to the manufacturer’s instructions. This assay uses a three-step indicator 
(incubation with immobilized and free antibody, enzyme conjugate and substrate) to 
detect the presence of procollagen, a larger precursor molecule, as a stoichiometric 
representation of type I collagen (see Section 1.4).  
Briefly, serum samples were first diluted with an assay buffer at 1:12 and incubated in 
microtitre-plate wells coated with purified murine anti-Collagen-I carboxyl propeptide 
(CICP) at room temperature (18-25°C) for 120 ±5 minutes. After three washings with 
buffer solution, the wells were incubated with rabbit anti-CICP antibody for 45-50 
minutes at room temperature. The molecules were then tagged by incubating them for 
45-50 minutes at room temperature with a lyophilised goat anti-rabbit IgG antibody 
conjugated to alkaline phosphatase. Following a further three washings with buffer, the 
final incubation with a p-nitrophenyl phasphatase substrate for 30-35 minutes at room 
temperature was done, and the reaction ended with addition of Stop-Solution. Optical 
density was read at 405 nm and sample results analysed after correcting for dilution 
 
 
 
 
 
 
 
 
3. Results        
 
3.1 Physical Parameters      
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3.1.1. Cell Morphology 
 
All cultures began as non-confluent fibroblastic layers. Partial obstruction by red blood 
cells during the first few days of the study did not significantly hinder micrographic 
documentation, as these red blood cells were gradually removed over the course of 
medium replacement, allowing an unrestricted view of the cell layer.  
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LEGEND for Cell Morphology Table 3-1:   
 
            1    Line 1 =degree of layer confluence: spar=sparse / int=intermediate /       
Day n                                                        c= fully confluent / n-c=nonconfluent 
Tab. 3-1: Influence of TGF-ß, IGF-I, PDGF and bFGF on Cell Morphology. Cell shape and layer 
development were observed and changes noted. 1)Cells were described as having one of four 
possible shapes: spindle-form, polygonal (multi-faceted), cuboidal and filamentous. 2) Confluence of 
the cell layer was described as being confluent or non-confluent, with degrees of confluence: sparse, 
intermediate or fully confluent (dish surface covered completely). 3) The macroscopic appearance of 
the cell layer was characterized as having a whorled appearance, islet-form (isolated cell groups), or 
nodular (raised cell-aggregates).  
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  2    Line 2 =appearance of cells: s=spindle / p=polygonal / cu=cuboidal 
                          f=filamentous 
   3    Line 3 =appearance of layer: w=whorled / isl=islet-form / nod=nodular 
 
 
 
 
 Cell Morphology: Photographic Examples 
 
The following images are examples of the morphological distinctions made during 
observation of cell development:  
 
a) Degree of layer confluence: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) Types of Cell Shapes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confluent cell layer : this formation was present only 
after Day 10 in all cultures; variations between the 
confluent and non-confluent stages were designated 
“sparse ” or “intermediate ”. 
 
 
 
Non-confluent  cell layer: the upper half of the 
photograph shows a solid layer formation, which is 
either sharply demarcated or branching into areas of 
the culture plate not yet covered by cells. 
Nodule : the formation indicated by the white arrow 
shows a bone nodule situated on a small cell-islet . 
The rest of the image consists of scattered individual 
cells which are not part of any larger cell layer. 
Filamentous cells (solid arrow)  were seen as 
strand-like formations, primarily, but not exclusively, 
during stages of cell expansion. The dotted arrow 
indicates one of the polygonal cells, which could not 
be classified in any of the previous categories.  
Spindle-shape : as shown by the solid arrow, the 
majority of matrix cells assumed an elongated form 
with the central cell nucleus. The dotted arrow 
indicated a cuboidal cell of the type which mainly 
floated free, not as part of any structure. 
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3.1.2. Bone Nodule Formation 
 
We observed the presence of nodules (see Section 1.4), which stained positively for 
calcium, in all groups, including control. Nodule count, time and duration of presentation 
varied widely between groups, as presented in the following diagrams. Even though an 
initial 7 days were allowed for culture growth to begin before any nodule count was 
made, in none of the groups were any nodules observed until Day 19. For each set of 
results, control value was set at 1,0 in order to permit comparison between the groups: 
 
IGF-I gave variable results depending on concentration (Fig. 3-18). In general, there 
seemed to be an earlier increase in nodule formation in the 10ng/mL (Day 19) than in the 
1 ng/mL group (Day 25). However, the latter group reached a higher count relative to 
control. By Day 31, both groups had returned to levels close to control. 
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 Fig. 3-1. The Influence of IGF-I on Bone Nodule Induction 
 
PDGF  nodule count (Fig. 3-19) showed a similar pattern between the two 
concentrations. Both the 1 and 10ng/mL groups exhibited a slight rise above  
Fig. 3-2  The Influence of PDGF on Bone Nodule Induction  
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control on   Day 25, (with the 10ng/mL group producing a higher count) and had returned 
to control levels by Day 31. 
 
   
 
The bFGF plates (Fig.3-20) clearly showed a reduction in the number of nodules 
counted in comparison to the control group. Not only were nodules in both the 1 and 
10ng/mL groups absent until Day 25, but also the absolute count was in both 
concentrations below that of control. 
 
 
   
  Fig.3-3 The Influence of bFGF on Bone Nodule Induction 
 
 
For TGF-ß (Fig. 3-21), the nodule count showed its greatest rise in the 10ng/mL group 
on Day 19. Afterwards, it’s levels dropped close to that of control until Day 31. The 
1ng/mL group also exhibited nodules from Days 19-31, but remained below control for 
the duration of the study.  
   
  Fig. 3-4 The Influence of TGF-ß on Bone Nodule Induction 
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3.2  Staining Procedure  
 
3.2.1 Calcium content as quantified with v. Kossa Stain 
 
All cultures stained positively for calcium. Generally, each group reached what appeared 
to be a 'staining maximum', before and after which colour intensity was noticeably 
weaker. In addition, there seemed to be a positive correlation in all growth factor groups 
between the percentage of surface area stained and the intensity of stain uptake.  Each 
plate received a rating (as outlined in Section 2.4.2.), according to the total surface area 
covered by stain, and according to the depth of stain intensity. The following illustrations 
(Fig. 3-5, 3-6, 3-7,  3-8, 3-9) are based on the results listed in Tables 3-2 and 3-3, and 
depict the rating assigned each of the results obtained on days 7,13,19, 25 and 31. The 
height of the histogram bar reflects the relative size of the area stained, whereas the 
colour of each bar reflects the intensity of Kossa stain.  Fig 3-9 depicts a summation of 
the relative course of all growth factors as given by layer rating points for each day. For 
the sake of simplicity, all treatment groups in this diagram are displayed as though 
compared to a single control; control plates in Groups 1 and 2 both exhibited the same 
layer rating even though taken from different subjects (see Table 2-1 and 2-2). 
 
 
                 Day 7          Day 13       Day 19  Day 25   Day 31  
           
                      Layer    Colour   Layer     Colour  Layer    Colour     Layer     Colour   Layer    Colour  
 
Control 0 0 1 1 1 1 1 2 1 1  
IGF-I 1ng 0 0 1 1 1 2 2 2 1 1  
IGF-I 10ng 0 0 1 1 1 2 2 2 1 1  
PDGF 1ng 0 0 1 1 3 3 2 2 2 2  
PDGF 10ng 0 0 1 1 3 3 2 2 2 2  
 
Tab.3-2: v Kossa Stain Intensity: Quantification of percentage of layer stained and depth of colour using 
score gradient as outlined in Table 2-3. 
 
                         Day 7      Day 13   Day 19    Day 25  Day 31 
  
               Layer   Colour Layer Colour Layer Co lour Layer Colour Layer Colour  
 
Control 0  0 1 1 1 1 1 2 1 2  
bFGF 1ng 0 0 2 1 2 1 2 1 1 2  
bFGF 10ng 0 0 2 2 2 2 2 1 1 1  
TGFß 1ng 0 0 0 0 0 0 1 1 1 2  
TGFß 10ng 0 0 0 0 0 0 1 2 1 2 
 
Tab. 3-3: v Kossa Stain Intensity: Quantification of percentage of layer stained and depth of 
colour using score gradient as outlined in Table 2-3. 
 
The IGF-I plates exhibited identical results in both concentrations. Until Day 19 less than 
30% of the surface stained positive, after which an increase in both surface area and 
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stain intensity above control was noted. This returned to initial levels by Day 31.  The 
PDGF group showed its strongest gain in area and stain intensity on Day 19 (60-90%), 
considerably stronger than control. PDGF then dropped to between 30- 59% for the 
remaining measurements. The bFGF cultures showed a significant level of surface 
staining on Day 13; moreover, opaque areas the 10ng/mL group were induced early in 
the study (Day 13) and then tapered off. Its 1 ng/mL counterpart did not show opacity 
until Day 31.Finally, TGF-ß showed very little tendency to stain, remaining negative until 
Days 25-31, and even then, only exhibited stain uptake in below 29%. This was inferior 
to the control group, which had begun to stain by Day 13.  
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Fig. 3-5: Influence of IGF-I on Culture Mineralization as Quantified by von Kossa Stain Technique.  
Interpretation of Rating: 0= No stain, 1=1-29% of surface stained; 2= 30-59%,  3=60-90% 
 
 
 
 
Fig. 3-6: Influence of PDGF on Culture Mineralization as Quantified by von Kossa Stain Technique.         
Interpretation of Rating: 0= No stain, 1=1-29% of surface stained; 2= 30-59%,  3=60-90% 
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Fig. 3-7: Influence of bFGF on Culture Mineralization as Quantified by von Kossa Stain Technique. 
Interpretation of Rating: 0= No stain, 1=1-29% of surface stained; 2= 30-59%, 3=60-90% 
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Fig. 3-8: Influence of TGF-ß on Culture Mineralization as Quantified by von Kossa Stain Technique. 
Interpretation of Rating: 0= No stain, 1=1-29% of surface stained; 2= 30-59%, 3=60-90% 
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Fig. 3-9 – Summary of relative layer rating between treatment groups based on percent of layer stained
 by v. Kossa method. 
 
3.2.2 Photographic Record of Calcium Content as Quantified with v. Kossa Stain 
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Day 19 
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Day 25 
IGF 1µg 
Day 31 
IGF 1µg 
Day 7 
The Effect of IGF 1µg On the Quantity of Calcium Content in In Vitro Cultures, Made Visible By 
von Kossa Staining Technique and Photographed With an hp Photosmart 715 Digital Camera. 
Slow progression with peak calcification by Day 25. 
 - 34 - 
 
 
 
 
 
 
 
 
IGF 10µg 
Day 19 
IGF 10µg 
Day 25 
IGF 10µg 
Day 31 
IGF 10µg 
Day 13 
IGF 10 µg 
Day 7 
The Effect of IGF 10µg On the Quantity of Calcium Content in In Vitro Cultures, Made Visible By 
von Kossa Staining Technique and Photographed With an hp Photosmart 715 Digital Camera. Slow 
progression with peak calcification between Days 19- 25. 
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Accelerated calcification with peak production approximately Day 19. 
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The Effect of TGF-ß 10 µg On the Quantity of Calcium Content in In Vitro Cultures, Made Visible By 
von Kossa Staining Technique and Photographed With an hp Photosmart 715 Digital Camera. 
Gradual calcification with maximum production after Day 25. 
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3.3 Biochemical Parameters . 
 
3.3.1. Osteocalcin 
 
The enzyme immunoassay method of detecting osteocalcin, described in 2.4.1., allowed 
us to follow the progression of osteocalcin production in each of the cultures. In one set 
of results, the absolute levels are given; in the second, the control value is set at 100% 
in order to allow comparison between the experimental sets.  
 
IGF-I induced osteocalcin levels which were, for the most part, below those of the control 
group. The 10ng/mL group in particular ran in a pattern that was almost diametrically 
opposed to that of the control, showing a “second peak “ spike at Days 13-19. This peak 
was also visible in the 1ng/mL group when graphed as a percent of the control value 
(Fig.3-10); in absolute values, this group showed a stable pattern with a slight rising 
tendency. 
 
Fig. 3-10: Influence of IGF-I on Osteocalcin Levels at 1ng/mL and at 10 ng/mL: 
Relative Values (control=100%)      
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Fig. 3-11 : Influence of IGF-I on Osteocalcin Levels at 1ng/mL and at 10 ng/mL 
: Absolute  Values 
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PDGF showed a distinct rise in both in both concentrations above the control group 
(Days 13-19), whereby the 1ng/mL group reached a higher absolute value (Fig. 3-13). 
After Days 19-25, OC levels began sinking to levels similar to control until the end of the 
study.      
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Fig. 3-12: Influence of PDGFon Osteocalcin Levels at 1ng/mL and at 10 ng/mL: 
Relative  Values (control=100%) 
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Fig. 3-13  Influence of PDGFon Osteocalcin Levels at 1ng/mL and at 10 ng/mL:
 Absolute Values                    
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bFGF exhibited a sharp rise in the 1ng/mL group, which sank after Day 13 and thereafter 
remained in the vicinity of the control values. The 10ng/mL group rose more slowly 
above control, reaching its highest peak on Day 25 and then rapidly falling to control 
levels (Fig. 3-14 and 3-15). 
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Fig. 3-14: Influence of bFGF on Osteocalcin Levels at 1ng/mL and at 10 ng/mL:
 Relative Values (control=100%) 
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Fig.3-15 Influence of bFGF on Osteocalcin Levels at 1ng/mL and at 10 ng/mL:      
Absolute Values 
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TGF-ß clearly showed a slow rise, reaching levels above control on Day 13 in the 1 
ng/mL group and on Day 19 in the 10 ng/mL group. Both these groups maintained a 
rising tendency, ending with measurements significantly higher than at the start of the 
study. 
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Fig. 3-16: Influence of TGF-ß on Osteocalcin Levels at 1ng/mL and at 10 
ng/mL: Relative Values (control=100%) 
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Fig. 3-17: Influence of TGF-ß on Osteocalcin Levels at 1ng/mL and at 10 
ng/mL: Absolute Values 
 - 41 - 
 
 
3.3.2. Procollagen-I Levels  
 
IGF-I added to culture noticeably influenced the levels of Procollagen-I; both the 10µg/L 
and the 1µg/L groups reached measurements twice those of control, with the1µg/L group 
superseding its 10µg counterpart.  Absolute Values (Fig3-22) show a steady climb in all 
groups, whereas Relative Values (Fig.3-23) reveal that higher concentrations of IGF-I 
caused as earlier peak (Day 19 vs. Day 25) in Procollagen levels.  
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 Fig.3-18 The Influence of IGF-I on Procollagen Levels: Absolute Values 
Fig.3-19 The Influence of IGF-I on Procollagen Levels: Relative Values 
(Control=100%) 
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PDGF also caused an initial induction of Procollagen-I. Absolute Values (Fig.3-24) show 
a rise in all groups, with both PDGF concentrations running a similar course compared to 
each other: levels rose approximately two times higher than control on Day 19 (Fig.3-25). 
Although the control and treated groups significantly diverged during Days 13-25, by Day 
31 they had arrived at an endpoint in close proximity to one another. 
 
 
     
    
             
 
 
 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-20 The Influence of PDGF on Procollagen Levels: Absolute Values 
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Fig.3-21 The Influence of PDGF on Procollagen Levels: Relative Values 
(Control=100%) 
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 bFGF groups exhibited a recognizable pattern of Procollagen induction, especially when 
displayed as Relative Values (Fig.3-27). Here we saw an early spike in both 
concentration groups, (higher in the 10µg/L group) after which both dropped below 
control. This was followed by a steady climb as shown in Absolute Values diagram (Fig. 
3-26) in the 1µg/L group and a slow drop in the 10µg/L group. 
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Fig. 3-22  The Influence of bFGF on Procollagen Levels: Absolute Values 
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Fig.3-23 The Influence of bFGF on Procollagen Levels: Relative Values 
(Control=100%) 
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TGF-ß also showed a noticeable effect on Procollagen-I levels, but in a negative rather 
than in a positive sense. The Absolute curve (Fig. 3-28) showed a steady climb in both 
concentration groups, but the Relative Values (Fig.3-29) revealed that the induction of 
Procollagen-I was especially inhibited at the outset of the study (Day 13). For the entire 
period of measurement, the TGF-ß group remained below control. 
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          Fig. 3-24 The Influence of TGF-ß on Procollagen Levels: Absolute Values 
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Fig.3-25 The Influence of TGF-ß on Procollagen Levels: Relative Values 
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4 Discussion  
 
In the following section, we will take a separate look at each of the individual growth 
factors, and attempt to explain their respective effects on each of the parameters. For 
each growth factor, a summary of the in vitro effects as described in the literature is 
given, along with an explanation of their effects on the parameters as described in this 
study: cell morphology, bone nodule formation, and, where relevant, adipocyte formation. 
The significance of calcium content, as well as the expression of biochemical proteins 
osteocalcin and collagen will be examined in light of these findings.  
 
4.1 IGF-I 
 
As discussed in Sec.1.3., IGF-I is one of the most well-studied regulators of bone 
growth; it can serve in either an anabolic or catabolic function, depending on the 
presence or absence of certain IGF-binding-proteins (IGFBP's).  The physiological 
effects of IGF-I can be summarized as follows: IGF-I has been shown to stimulate 
proliferation and matrix synthesis in in vitro cultures of osteoblast-like cells, i.e. it 
increases the replication of cells of the osteoblastic lineage (probably preosteoblasts) 
and enhances osteoblastic collagen synthesis and matrix apposition rates.  IGF-I 
exhibits a stronger osteogenic effect in synergism with other growth factor 65.  
 
The present study concerns itself with the effects of IGF-I on pre-osteoblasts and 
osteoblast-like cells in human stem cell culture, making it among the few in vitro studies 
to use human instead of animal bone cells, and mesenchymal stem cells (MSC) from 
marrow instead of bone cells taken from mature bone. Although the physiological 
mechanisms are complex and incompletely understood, this study made the following 
general observations on the effects IGF-I on human MSC:  
 
1. IGF-I was capable, in concentrations of 1 and 10 ng/mL, of increasing cell survival 
and raising certain biochemical parameters, which are characteristic of the 
osteoblastic phenotype, above those of a non-treated control group in human 
MSC. We observed a similarity in the effects of these two concentrations, but a 
difference in regard to the timing of these effects when viewed temporally. 
 
2. Even though previous studies (for the most part using rat calvarial cell cultures or 
osteoblast cell lines) show the ability of IGF-I to raise osteocalcin levels 65, the 
present study suggests that these actions of IGF-I do not necessarily hold true for 
human MSC cultures. Mohan and Baylink (1993) suggest that binding proteins are 
produced in differing amounts in rat vs. human osteoblasts, providing a possible 
explanation for variant findings 167.  
    
     The key to understanding the effects of IGF-I in this study lies not in the observation 
of dose-dependant activity but in the temporal pattern of IGF-I behaviour over the course 
of the study. Following the steps from culture confluence to bone nodule formation help 
understand this process: 
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Morphology: Cell cultures tend to have a limited life span of between four and six weeks 
(unpublished observations) beyond which the cell layer becomes more sparse and 
begins to spontaneously detach from the plate. This reflects programmed cell death 
(PCD), or apoptosis, and is the process by which cells induce their own demise. 
Osteoblast survival in mouse calvarial cells in vitro is significantly increased by IGF-I 64, 
and it was of interest to observe whether this effect carried over to human MSC. Based 
on cell morphology results (Tab. 3-1), we noticed that even though control group and 
IGF-I groups had reached confluence together at the outset, during terminal stages 
(signified by increasing non-confluence and insular layer formation), IGF-I groups in both 
concentrations had remained whorled and confluent for a full nine days longer than 
control. Our results suggest that in human MSC, IGF-I is able to increase osteoblast 
survival. While this effect may result from some other, unidentified elements in serum, 
(for example in Fetal Calf Serum, FCS), this postulation is supported by the fact that 
bFGF, also a known stimulant of osteoblast survival 64, exhibited similar results (see 
Section 4.2 below). In addition, TGFß, which seems unable to increase survival in 
mouse osteoblasts 64, also exhibited less confluence than control in our study (see 
below).  
 
Culture Mineralization and Nodule Count: A further component of this study, which gave 
insight into the effects of IGF-I on the lifespan of MSC cultures, is the calcium content as 
quantified by von Kossa stain. We observed a certain 'maximum' stain intensity that was 
reached at a different point and had variable duration (plateau) in each of the groups 
(see Fig.3-9). This plateau was consistently higher in each of the growth factor groups 
than in TGFß or control; the observation that each 'maximum' was subsequently followed 
by a drop in intensity, even before the end of the study, suggests that the cultures had 
reached a high-point of productivity and had begun to apoptose. Interestingly, IGF-I 
induced this stain 'spike' latest of all groups, on Day 18; Hill et al (1997) suggest that 
IGF-I seems to increase osteoblast survival by inhibiting programmed cell death (PCD) 
rather than inducing increased proliferation in mouse calvariae 64, and so it is possible 
that IGF-I induces primarily an initial proliferative stimulus to osteoblasts in human MSC, 
followed later by maximum matrix calcification based on programmed cell life. In other 
words, IGF-I may delay programmed cell maximum (and thereby programmed cell 
death) by some uninvestigated mechanism.  
 
This model is strengthened by the results of bone nodule count (nodule formation 
represents a measure of the bone culture's ability to form calcified structures similar to 
woven bone, Sec. 2.4.3). Studies using bone and marrow cultures, as described in Sec. 
1.4.2. have demonstrated the expression of bone nodules in animal 1,122,123 and human 
bone 107 cultures. In human marrow stromal cells, however, formation of nodules was not 
observed by Chen et al (1994)135, which stands in contrast to this study, but which may 
be explained in part by differing sources of human marrow (iliac crest aspirates 
compared to washed marrow from split human ribs).   
As mentioned, the maximum calcification was observed on Day 18, and the maximum 
nodule count in the 10ng/mL group occurred on Day 19. The maximum nodule count in 
the 1ng/mL occurred later on Day 25. If indeed IGF-I does delay programmed cell 
maximum at physiological concentrations, the fact that 1ng/mL induced a later and a 
higher nodule count may signify a more physiological effect in hMSC. Alternately, these 
concentration-dependent differences could indicate that IGF-I in higher concentrations 
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may be a more effective initial stimulator of osteoblast function; levels of nodule growth 
(and osteocalcin) tended to show a stronger start in the 10ng/mL group. This may in fact 
be due to IGF-I stimulation of osteoblast proliferation i.e. an increase in the absolute 
number of osteoblasts in MSC. 
Significantly, control groups in the grading of stain intensity did not exhibit any sort of 
noticeable maximal peak;  this could also result from the relative insensitivity of our 
quantification method (v. Kossa stain).  
 
   Osteocalcin (OC) and Collagen: Generally, absolute osteocalcin levels in both 
concentrations remained below control levels over a 31-day course, rising only slightly 
above control group on Day 19, while collagen (detected as procollagen) was stimulated 
to rise above control. This partly agrees with work done by Langdahl et al (1998), who 
observed, using IGF-I on trabecular explants and human MSC cultures, that osteocalcin 
and procollagen production were not significantly altered by addition of IGF-I alone in 
MSC 152.  One reason for the discrepancy in procollagen results could lie in the age of 
the subject from whom the cells were taken; Denis et al  report that the effects of IGF-I 
on pig bone cells is strongly dependent on maturation and origin of cells 154. In the 
graphic representation of IGF-I induction of OC relative to control levels set at 100% 
(Fig.3-10) we observed a pattern by which IGF-I at 10ng/mL seemed to induce a peaked 
course while IGF-I at 1ng/mL exhibited only a slight rise at midpoint in the study before 
returning to sub-control levels. This peak in OC production in both groups came on Day 
19 of the study, which was also the same time at which procollagen levels reached their 
maximum peak relative to control (Fig. 3-23). 
 
Broadly, procollagen levels in both IGFconcentration groups were stimulated to rise 
similar to control groups, until Day 13; at this time control reached a plateau, whereas 
procollagen in the IGF-I groups continued to rise and reach a plateau later, and at an 
overall higher level than control (Fig. 3-22) on Day 19.  Significantly, it was noticed that 
the peak procollagen levels relative to control (see Fig. 3-23) occurred on precisely the 
same days as the same-concentration group in Bone Nodule count (Fig. 3-18), i.e. the 
10ng/mL group in Nodule count and Procollagen Level reached maximum on Day 19 
and the1ng/mL on Day 25. This confirms the relationship between procollagen formation 
and nodule formation in MSC culture. 
 
 Collagen and OC are both expressed after osteoblastic differentiation in bone culture, 
but Procollagen is expressed before OC (see Fig. 1-8). Knowing this, and that IGF-I 
enhances osteoblastic collagen synthesis and matrix apposition rates, we suggest the 
following model: IGF-I enhances, but may also delay osteoblastic collagen synthesis and 
matrix apposition rates in MSC. IGF-I may initially increase the replication of cells of the 
osteoblastic lineage, which produce procollagen longer than untreated culture, resulting 
in an overall increase after a temporal postponement of matrix formation and 
calcification. The failure of IGF-I to raise OC levels in this study may be explained when 
we consider the function of OC: it limits bone matrix resorption (see Sec. 1.4) and so 
seems to function as a negative regulator of mineralization. OC perhaps did not increase 
due to the lack of osteoclasts with resorptive capabilities in IGF-stimulated MSC culture, 
i.e. if there is no significant osteoclastic resorption of matrix, then there is reduced need 
for OC production. It is known that IGF-I functions as an important regulator of 
osteoclastic bone resorption in unfractioned bone cell or pre-existent osteoclast cultures 
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92. Mochizuki et al (1992) showed that stimulation and activation of osteoclasts occurred 
upon addition of IGF-I to haematopoietic precursors, but the resorptive potential of the 
osteoclast-like cells was not demonstrated  92,93. 
 
 
Summary:  
The conceivable mechanisms for these processes are innumerable (e.g. reduced or 
increased number of or sensitivity to binding proteins), but taken together, the results 
suggest that the role of IGF-I in human MSC is as a stimulator of the osteoblastic 
phenotype and a temporal regulator of development. Cell morphology, nodule count, 
procollagen levels and mineralization suggested both an increase as well as a delay in 
maximum cell production, while OC levels, which did NOT rise above control, indicated a 
different influence of IGF-I on MSC as opposed to calvarial (bone cell) culture. IGF-I may 
regulate osteogenesis of human bones in a dose-dependant manner; an optimal 
('physiological') concentration may have osteogenic effects superior to concentrations 
above or below 152. Any significant proliferative effects of IGF-I seems to depend 
considerably on interactions with other GF's, while IGF-I alone can still evoke a response 
in terms of culture lifespan and calcification. 
 
 
 
 
4.2  PDGF 
 
Due to the relative lack of previous PDGF studies using human bone or marrow culture, 
it is difficult to substantiate all our findings based on foregoing work. However, some 
definite patterns emerged, some of which corresponded to previous animal models, 
others of which seemed to indicate a different response in human MSC. The effects of 
PDGF on animal culture (rat calvariae) in vitro can be summarized as follows: Generally, 
PDGF has effects similar to bFGF; PDGF tends to increase less-differentiated cells in 
the osteoblastic lineage (mitogenesis) but not their differentiation into mature osteoblasts 
79.  PDGF can show varying production of bone proteins depending on the cell’s 
developmental stage (i.e. whether bone or stromal cells) and temporal factors (i.e. the 
time period of exposure to PDGF) 55. We made the following observations of PDGF 
effects on human MSC:  
 
1. PDGF was capable, in concentrations of 1 and 10 ng/mL, of increasing culture 
activity, cell survival and layer calcification, as well as raising procollagen 
levels above those of a non-treated control group in human MSC.  
 
2. OC levels and bone nodule count were stimulated to a moderate rise for a 
short time above control, then returned to levels below or equal to control.  
 
Morphology and Cell Survival: Cell-morphology observations showed the earliest 
complete confluence of any of the growth factors except bFGF (Tab.3-1); cell layer 
remained a confluent and tightly-packed cell organization to the end of the observation 
period. Culture activity was also highest in the PDGF groups (in concentrations of 
1µg/mL and 10µg/ml) lending support to PDGF's mitogenic and proliferative function. 
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Both these finding are corroborated by Kim et al  (1997), who showed maximum PDGF-
induced proliferation during the first 48 hours of a 120 hr. observation period, also using 
10 µg/ml 85. 
As regards cell survival (discussed in Sec. 4.1), PDGF is reported to be unable to 
increase cell survival on its own and could only do so in the presence of other growth 
factors or insulin 64. Since we observed an increase in culture survival similar to bFGF 
and IGF-I, which are known to increase survival on their own, it seems reasonable to 
assume that the effects on cell life span in this study were due to PDGF. If this is true, 
we must keep in mind that PDGF can only increase osteoblast survival in synergism with 
other growth factors such as IGF-I, an effect possibly due to IGF-I receptor modulation 
64.This would mean that a secondary growth factor, possibly IGF-I produced in situ by the 
cell layer itself, was potentiated by PDGF to increase cell survival.  
 
Culture Mineralization and Nodule Count:  As mentioned, PDGF can both stimulate bone 
matrix apposition, although the mechanisms for this process have been only 
incompletely described. In the present study we report a stimulation of matrix formation 
and calcification; PDGF showed the highest Kossa-stained surface area, (Fig.3-9), the 
most intense depth of stain (Fig.3-6), the earliest 'peak' in calcification and the longest 
duration of cell staining (Fig.3-9) of all growth factors observed, suggesting a high level 
of initial activity. Long-term mineralising cultures, however, are characterised by the 
formation of calcified nodules, and the nodule count in both PDGF concentrations 
revealed a moderate rise above control on Day 25. This did not seem to be a long-
lasting effect, and could have been a short “spike” due to a numerical increase in 
osteoblast precursors at the outset. Other studies have reported analogous results with 
PDGF at over 30 ng/mL for four days showed an increase in proliferation for the first 48 
hours of exposure but not during the second 48 hours; this effect could be due to a 
downregulation of PDGF receptors 85.   
 
PDGF has also been reported to increase bone resorption and layer degradation, 
possibly via stimulation of collagenase and activation of osteoclasts 77,164. This effect is 
associated with increased erosion of bone surface in rat calvariae, and may be mediated 
by cytokines such as Interleukin-6 172. We observed no morphological evidence of 
increased degradation of cell layers as documented micrographically, but rather an 
overall increase in procollagen levels (Fig. 3-24), which suggests a number of 
possibilities: PDGF may exert a stronger resorptive and/or nodule-inhibiting effect in 
bone-derived than in MSC-derived culture, or one of the protein or cytokine mediators 
may not be present in MSC in sufficient quantities to activate this effect. Like other 
growth factors, the effects of PDGF seem to be dependant on developmental stage of 
the cells; layer degradation may come at a later stage or at a different concentration.   
 
Osteocalcin (OC) and Collagen: OC level-results were more similar to previously 
published findings. Hock et al (1994) reported PDGF tendency to stimulate replication 
but not differentiation of rat osteoblast-like cells; our results showed an initial increase in 
OC levels, especially at lower concentrations, reaching a peak by Day 19. This was 
followed by a drop to levels below control (Fig. 3-12 and 3-13). This pattern is in itself 
parallel to PDGF's early mineralization peak, i.e. mineralization, following organization of 
cells (possibly into nodules) is a time which is generally associated with an increase in 
the expression of growth proteins. Nodule growth, while lower relative to IGF-I and 
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TGFß, reached its maximum shortly after the temporary rise in OC levels. These findings 
agree with results published by Yu et al (1997) who identified PDGF as an early 
stimulator of osteoblast proliferation in long-term culture, followed by a later ‘drop’ in AP, 
collagen, OC and bone nodules 186. 
  
The results of procollagen measurements also showed a sharper rise at the start, as 
early as Day 13, and a highpoint on Day 19 (Fig.3-25), later tapering off to control levels. 
These findings are partly in support of Pfeilschifter et al  (1992) who reported the 
increase in new bone formation in PDGF-treated rat calvariae 55, and partly in support of 
other studies which suggest that any collagen increase is subsequent and secondary to 
the mitogenic effect (i.e. early numeric proliferation of osteoprogenitor cells) of PDGF 
70,79. Taken together, the findings are internally consistent with a growth factor that has a 
mitogenic and proliferative function. Like bFGF, the early rise in parameters (cell count, 
layer confluence, procollagen) followed by the moderate rise OC and nodules suggest 
the following model: PDGF stimulates osteoprogenitor cells in hMSC to proliferate, but 
may not promote the differentiation to mature osteoblasts. The rise in OC and nodules 
may be the secondary result of proliferation in the early stages of culture.  
 
Summary: 
These results confirm the role of PDGF as an 'early response' growth factor; it is 
secreted by platelets and involved in biochemical and chemotactic events thought to be 
important in initial wound healing. Moderate bone nodule count, early confluence and 
rapidly rising collagen levels lend further weight to the suggestion that in human MSC, 
PDGF functions primarily as stimulator of those elements necessary to respond to some 
trauma to the skeletal system or skin.  
 
 
4.3 bFGF 
 
Like IGF-I, bFGF has been shown to have a variety of functions, as outlined in Sec. 1.3. 
It is important to keep in mind that as in the case with many physiological regulators in 
vitro, bFGF's effect on bone culture depends heavily on the origin and developmental 
stage of the cells 155. To review, bFGF seems to exert a largely mitogenic effect on 
cultures of animal calvariae or periostium-derived mesenchymal cells i.e. it induces an 
increase in cell division without a direct increase in bone parameters 3,70,72 . Furthermore,  
bFGF seems to have a second (biphasic) role in stimulating the osteogenic potential of 
stromal bone marrow cells: not only does bFGF stimulate the proliferation of 
uncommitted progenitors and osteoprogenitors, but it also participates in stimulating the 
later differentiation of already committed osteoprogenitors 69,134,138. 
 
In the present study, we confirm the regulatory and mitogenic effects of bFGF on the 
osteoblast phenotype in human marrow culture. Although the physiological mechanisms 
are complex and incompletely understood, this study made the following general 
observations on the effects bFGF on human MSC:  
 
1. bFGF was capable, in concentrations of 1 and 10 ng/mL, of increasing cell 
survival and matrix calcification, as well as raising osteocalcin (OC) levels, 
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which is characteristic of the osteoblastic phenotype, above those of a non-
treated control group in human MSC.  
 
2. bFGF either had no effect or decreased procollagen levels and bone nodule 
formation. 
 
3. bFGF exhibits a tendency to promote the development of the adipocyte 
phenotype.   
 
Morphology and Cell Survival:  Results of cell morphology showed that bFGF cultures 
were among the first (along with PDGF) to reach confluence of any treatment group (Day 
3 in the 1 ng/mL group, as opposed to Day 6 in Control) and like IGF-I, remained 
confluent until the end of the study on Day 31 (control showed only intermediate, insular 
growth formations after Day 15). This lengthened culture lifespan suggests that bFGF 
increases osteoblast survival in human MSC, as has been demonstrated in neonatal 
mouse calvariae 64. In studies with animal tissue, bFGF, similar to IGF-I, prolonged cell 
life by inhibiting programmed cell death (PCD), but always in cooperation with a second 
growth factor, e.g. PDGF. This effect seems to hold true for human stem cells, likely due 
to interactions of bFGF with an unknown single, or multiple, second factor(s).  
 
Culture Mineralization and Nodule Count:  With regard to matrix calcification, we 
observed that bFGF exhibited the strongest start of all treatment groups; already by Day 
13, the stain intensity had reached a level two times higher than control. It maintained 
this maximal plateau almost until the end of the study, a pattern which suggested a 
“steady” cell state of matrix production, for at no time did bFGF ever exhibit a sharp 
“spike” pattern, as did IGF-I (on Day 25) or PDGF (on Day 19) (Fig. 3-9). This 
substantiates previous reports of bFGF's ability to hold cells in a steady stem-state by 
inhibiting further differentiation 138; the level of calcification may have rapidly stabilized 
due to a certain cell population remaining as calcium-producers and attaining no further 
development. This is supported by Canalis et al (1988) who suggested that a bFGF-
mediated collagen increase in rat calvariae was due NOT to an increased production of 
this bone protein by osteoblasts but was rather a secondary, indirect result of the higher 
number of in vitro colonies that produce collagen and calcify 7.  
 
bFGF produced the least number of bone nodules of all factors observed; in both the 1 
and 10 ng/mL groups, no nodules appeared until Day 25, and did not produce more than 
20% of control levels. This suggests that although calcified matrix was present, it had not 
reached a sufficiently mature stage to produce nodules.  Four stages of matrix 
development are necessary to produce nodules (see Sec. 1.4): 1) cell proliferation with 
formation of multicellular layers; 2) cell differentiation; 3) cell activity with matrix 
formation and 4) matrix mineralization.  It is possible that the cell layer in the bFGF 
treatment group has reached a stage which contained some differentiated osteoblasts, 
but could not proceed to the next stages to form nodules due to the tendency of bFGF to 
hold some cells in an extended  “stem state”. Knowing that non-collagen proteins such 
as osteocalcin are not expressed until completion of a three-dimensional cell-layer 
microenvironment, we can assume by viewing the increased OC levels and matrix 
calcification that such a layer had been produced, but that the plateau of matrix 
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production reached was not enough to bring about the formation of great numbers of 
nodules (Fig. 3-20). 
 
 Osteocalcin (OC) and Collagen:  Osteocalcin levels were identical to control at the 
outset of the study  (Day 7) and exhibited a sharp rise thereafter; OC levels in bFGF 10 
ng/mL reached the highest point of any treatment group (Day 25) and generally 
remained above both control and the other GF groups in the second half of the study 
(Fig. 3-15). As described previously, OC is a relatively late protein marker (see Fig.1-8), 
being expressed after components of the stromal cell population have differentiated into 
osteoblasts. The mitogenic effects of bFGF may induce greater initial proliferation at the 
outset, leading to a later, secondary rise in OC when differentiation had occurred under 
the influence of autocrine GF.  This would be especially visible in the 10 ng/mL group, 
which peaked later than the 1ng/mL group (Day 25 vs. Day 13). The significant dose-
dependence seen in the OC results may be explained by previous reports which 
determined that bFGF proliferates optimally at a concentration of 0.3 ng/mL 134; clearly, 
the 1ng/mL group would induce a more rapid proliferation and therefore an earlier 
secondary raise in OC expression. 
 
Alternately, another explanation for bFGF-mediated increase in OC has been proposed 
by Schedlich et al (1994), who demonstrated the ability of bFGF to activate the 
osteocalcin gene, even in rat osteoblasts transfected with human osteocalcin promoter 
156. This would allow for an increase in OC even in the absence of significant numbers of 
differentiated osteoblasts. This premise is supported by the fact that bFGF at 1ng/mL 
reached levels similar to the 10ng group, and at a more rapid initial rate of ascent (Fig.3-
15), i.e. the lower concentration of bFGF is equally capable of activating the OC-gene in 
osteoprogenitor cells (dose-independent), but that the prolonged “stem-state” effect may 
be more noticeable at higher concentrations of bFGF (dose-dependant), leading to a 
slower rise in OC levels.  
Furthermore, the OC levels exhibited a certain “biphasic” distribution (peak in the 1ng/mL 
group on Day 13 as opposed to Day 25 in the 10ng/mL group).  bFGF may in effect 
exercise a later, second stimulatory effect on the further differentiation of osteoprogenitor 
cells already committed to some particular line of development.  In other words, 
continual expose to bFGF may stimulate an MSC culture to produce increased OC not 
once but twice: the first time, an initial rise in OC results from osteoprogenitor 
multiplication, and a second time when other osteoprogenitors which have been held in a 
“stem-state” are later committed to the osteoblastic lineage but still require further 
differentiation. 
 
The question whether higher OC levels are due to proliferation of osteoblasts or gene 
activation may be further clarified by looking at levels of procollagen; if bFGF can induce 
initial proliferation of osteoprogenitor cells, then at some point we expect a secondary, 
indirect rise in procollagen levels above control, which did not occur. This suggests that 
if levels of proliferation are not sufficient to raise collagen, cell number or bone nodules 
secondarily, then the rise in OC must be due to some other stimulation, e.g. OC-gene 
activation. 
 
 Alternately, if the increase in OC is due to secondary osteoprogenitor proliferation, then 
bFGF may have an inhibitory effect on procollagen expression. Previous studies have 
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demonstrated the ability of bFGF to stimulate 168 or inhibit 70 the production of collagen 
depending on the presence of certain factors in serum.  Kessler et al (1993) 
demonstrated the tendency of bFGF to inhibit collagen in the presence of heparin 169; 
since our absolute and relative results also show reduced or unaffected procollagen 
levels relative to control (Fig.3-26 and 3-27), there may be interactions of bFGF with an 
unknown third factor in serum or in culture. 
 
Adipocyte Formation:  One more aspect of bFGF function that needs to be considered 
involves its role in adipogenesis. Although not the thrust of this study, it warrants our 
attention because of the inverse relationship that has been postulated in several studies 
between adipocyte differentiation and the osteogenic capacity of stromal cells in bone 
marrow. Adipocyte differentiation in vitro is accompanied by a loss of gene markers 
consistent with an osteoblast-like phenotype 40,157. In addition, the osteoblast and 
adipocyte cell lineages are thought to be reciprocally related, due in part to the 
observation that the osteoblast stimulator Vitamin D3 inhibits adipogenesis 
149, 
suggesting that the absence of adipocytes is, however indirectly, associated with the 
presence of osteoblasts. Our aim was to screen for the appearance of all “non-bone” cell 
types, and we chose the easily recognisable adipocyte-like cells (see Sec 2.4.3), which 
were not only detected in our pilot studies, but also photographically depicted in the 
literature153,26. Any consideration of bFGF for clinical application must take into account 
its ability to influence the differentiation of marrow MSC toward the adipocyte phenotype. 
 
Some authors have noted the formation of adipocytes in the presence of human serum 
and glucocorticoids within 21 Days, but few or no adipocyte formation in Fetal Calf 
Serum (FCS) either with or without glucocorticoids 135,158. We have consistently 
observed some adipocyte formation (unquantified) in pilot marrow stromal cultures, and 
noted that in this study, bFGF groups clearly contained the greatest adipocyte formation. 
Kawaguchi et al (1998) observed de novo production of adipocytes in mice upon 
subcutaneous injection of gel augmented with bFGF, suggesting that this growth factor 
plays a role in the physiological production of fat tissue 155. 
 
Summary: 
Our results identify bFGF as a regulator of osteogenic potential in human MSC: 
increased culture survival and matrix “plateau” support bFGF’s ability to hold cells in a 
“stem-state”. Raised OC levels may be a result of mitogenic proliferation, but due to the 
low nodule count and unaltered collagen levels, it seems reasonable to suggest that 
mitogenic proliferation and differentiation to the osteoblastic phenotype was not 
significant in human MSC. bFGF may be able to active an OC gene in a biphasic 
manner. 
 
 
 4.4 TGF-ß 
 
As discussed in Section 1.2., TGFß is a multifunctional regulatory protein, present in 
large quantities in bone tissue. It has been associated with several aspects of bone cell 
biology, such as replication, differentiation and osteogenesis 159. These effects can be 
summarized as follows: TGF-ß inhibits MSC differentiation to osteoblasts, while 
stimulating proliferation of the osteoblasts themselves 47,49,50. The major effects of TGF-
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ß on cell growth and differentiation seem to be restricted to the proliferative phase of the 
culture, before the cells express a mature osteoblastic phenotype. This leads to an initial 
suppression of “mature bone cell“ markers, such as calcium deposition and nodule 
formation 50. However, continued exposure to TGF-ß leads cells to exhibit a second, 
positive (biphasic) growth response in the form of increased matrix and mineralization. 
These effects are dependant on maturity of the cells exposed to TGF-ß, as well as the 
concentration of GF. 
 
We report that, generally speaking, TGFß had a tendency to suppress the parameters 
associated with initial culture growth in human MSC, giving values close to or below 
those of the control group as well as the other growth factors. Parameters associated 
with bone nodule production were raised.  
 
1. 1 In concentrations of 1 and 10 ng/mL, TGF-ß had an inhibiting effect on cell 
count, procollagen levels and matrix calcification, and induced a noticeable 
decrease in cell survival. 
 
2. TGF-ß was capable of raising osteocalcin (OC) levels and bone nodule formation 
above those of a non-treated control group in human MSC.  
 
3. TGF-ß exhibits a tendency to decrease the development of the adipocyte 
phenotype. 
 
Morphology and Cell Survival:  One of the most remarkable observations in the TGFß 
group during the study concerned the layer morphology. Of all groups including control, 
only TGF-ß was unable to reach confluence at any point (Table 3-1) At best, it reached 
an intermediate level of layer formation, after which it rapidly became a sparse 
arrangement of isolated cuboidal cell aggregates, having no connection to each other. 
This suggested a shortened culture life span, and supports work by Hill et al (1997) 
identifying TGF-ß as a GF with no effect on either osteoblast survival or programmed 
cell death (PCD) 64. The absence of this effect could be related to density at which cells 
are cultured, as suggested by one study which established a correlation between PCD 
and in vitro plating density 64,188. 
In addition, TGF-ß- treated culture exhibited a largely cuboidal cell shape between Days 
9-24; this shape was only transitionally present in the other groups between Days 6-12. 
The addition of osteogenic supplements 107 and growth factors 62 to medium is known to 
influence cell morphology, but the significance of this difference in cell shape is unclear. 
 
Culture Activity, Mineralisation and Nodule Count:  Previous studies indicate that TGF-ß 
exerts proliferative influence on periosteal osteoblast precursor cells and formation of 
new woven bone in vivo 50,161, but can inhibit bone formation and organization in animal 
cultures in vitro at as little as 0.1 ng/mL 50. The results of staining for culture calcification 
in both concentrations of TGFß showed a severely retarded layer formation and stain 
uptake relative to control or other treatment groups. The process by which MSC cells 
form a cell layer in vitro was described in Sec. 1.4. Briefly, cells proliferate initially to 
establish an extracellular matrix, forming a self-assembled environment enables them to 
organize into three-dimensional nodule structures and mineralise. TGFß is produced 
physiologically at the initial proliferation phase, but in a latent form 51. Once activated, for 
 - 55 - 
example by transient acidification, it has the ability to block progression to the next stage 
(such as morphological change and differentiation), but must be present at a time when 
cells are proliferating prior to expression of osteoblastic phenotype as in our study 162. 
Our results suggest that in human MSC, culture activity was impeded as indicated by low 
cell count (Fig.3-4), and mineralization was inhibited (Fig.3-7). TGF-ß allowed the initial 
formation of a thin cell layer through proliferation, but this layer was inhibited from 
normal growth; instead, it assumed the most nodular (cell-aggregate) appearance of any 
GF group, even though calcified nodules were not seen until Day 19. Matrix calcification 
and layer morphology in both concentration groups remained similar to one another, 
although it has been observed that TGFß blockage of layer is dose-dependant 50, 189. 
 
With regard to the increased nodule formation in the 10ng/mL group, our results were in 
agreement with a previous study in which bone nodules were stimulated in the presence 
of glucocorticoids and low serum but inhibited by TGFß in the absence of glucocorticoids 
123. We noticed that on Day 19 of the study nodule number in the 10 ng/mL group 
reached a peak similar in height to IGF-I, and higher than PDGF or bFGF.  These 
quantities then declined to levels close to control (Fig. 3-21). Nodules produced on the 
10 ng/mL group reached higher absolute numbers than in the 1 ng/mL group, which did 
not rise above control. This concentration-dependent difference is contrary to findings by 
Centrella et al (1991) who reported a decrease in culture stimulation at higher 
concentrations 190. This may be explained when one considers the relative strength of 
maximum doses used in other studies, in which TGF-ß was used at up to 50 ng/mL as 
highest dose 191. In any case, the high nodule count seemed to be correlated to the 
increased appearance of proteins OC and Procollagen, which also began to climb on 
Days 13- 19. The fact that nodules were well expressed at a point when calcified matrix 
was poorly developed is a phenomenon that will be clarified in the next section. 
 
Osteocalcin (OC) and Collagen:  The modest rise in OC levels (Fig. 3-17) was initially 
unexpected in light of previous findings which described the reduced expression of OC in 
TGF-ß-treated foetal rat calvarial culture 190,191,54,46  and the down-regulation of the OC 
gene by TGFß in rat osteosarcoma cells 159. However it is important to note that OC 
levels did not begin to differ substantially from control until after Day 19. This suggests 
that there was an initial suppression of OC during proliferation. Another important factor 
is the temporal sequence of expression for growth proteins 170; OC is a late-expression 
protein that rises in association with matrix and nodule formation. Knowing that TGFß 
inhibits differentiation of the osteoblast phenotype and promotes proliferation, it seems 
reasonable to suggest that in human MSC, TGFß allows an initial proliferation of 
osteoblast-like cells but when this phase is past, continues to suppress differentiation 
and thereby protein expression until organization of nodules and mineralization begins. 
This is described in the literature as a so-called biphasic effect, i.e. continuous exposure 
to TGF-ß leads to a bifunctional growth response from a negative effect in the 
proliferative phase to a positive growth effect during later maturation phases of the 
osteoblast developmental sequence 50. The later rise in OC would therefore be 
subsequent and secondary to proliferation, and was likely produced by osteoblasts 
beneath the surface of nodules as described in Sec. 1.4.  This hypothesis is supported in 
our results by the concomitant rise in Kossa-stained colour density / surface area  (Fig. 
3-7 and 3-9 respectively) and OC levels (Fig.3-16, 3-17).   
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TGF-ß exhibits the tendency to latently stimulate OC in human MSC cultures, but 
procollagen expression was clearly lowered. This finding is supported in one study using 
foetal rat culture 55,50, but other studies found an increase in procollagen using the same 
culture 171,54,46. The inhibition of procollagen expression may be a reflection of the low 
levels of calcified matrix present in the culture wells, although some researchers have 
not found a solid correlation between biochemical and histological determination of 
matrix apposition 55.  
 
In assessing these results and comparing them to previous findings, it is important to 
realize that the development of long bone involves two processes: intramembranous 
ossification (mesenchymal cells differentiate directly into osteoblasts, for bone growing in 
width), and endochondral ossification (mesenchymal cells in the periosteum differentiate 
first into chondrocytes and later into bone cells during periosteal healing and callous 
distraction). TFG-ß may play a more important role in periosteal healing (enchondral 
ossification) than in bone growth (intramembranous ossification) 72. In the context of our 
study, TGF-ß may have been initially suppressive of the osteoblastic phenotype because 
it is primarily a stage of bone growth; its later (biphasic) stimulation may have been, in 
effect, an attempt to ‘heal’ the culture by OC expression and local induction of nodules. 
 
Adiposity Formation: A final aspect of TGFß function (and Bone Morphogenetic Proteins 
generally) is the apparent ability to inhibit adipocyte formation (see Fig. 1-5). Studies with 
rat marrow and multipotent cell lines have suggested a reciprocal relationship between 
osteogenesis and adipogenesis, i.e. that commitment to the osteogenic lineage may 
occur only at the expense of adipocyte formation 40,157,163. Our results seem to confirm 
this action in human marrow; of all groups observed and recorded micrographically, only 
in TGFß was no adipocyte formation seen. 
 
Summary: 
Taken together, our results suggest that human MSC, when treated with TGFß, 
responds differently than previously reported results with animal cultures, taking 
methodological variations into consideration. We report the overall suppression of matrix 
formation and calcification and relative stimulation of cell aggregates into nodules with a 
relative and absolute increase in OC. 
 
 
   
 
 
 
 
 
 
 
 
 
5.  Review, Clinical Relevance and Future Direction s 
 
5.1 Summary 
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The foregoing study has confirmed the effects of four growth factors on osseous 
metabolic processes. To review, we have established that:  
 
IGF-I is a stimulator of the osteoblastic phenotype, a temporal regulator of development 
and is capable of increasing cell survival in human mesenchymal stromal cells. 
 
PDGF functions as an ‘early-response’ factor; it stimulates osteoprogenitor cells in 
human bone tissue to proliferate, but may not promote the differentiation to mature 
osteoblast 
 
bFGF did not significantly stimulate the osteoblastic phenotype, but may hold osteo-
progenitor cells in a “stem-state” for a protracted period. 
 
TGF-ß exhibits a biphasic regulation of osteoblast development involving initial 
suppression of matrix formation and later relative stimulation of cell aggregates into 
mineralised nodules 
 
Many previous studies have demonstrated the effects of growth factors on bone 
generation and metabolism beyond any reasonable doubt. The four growth factors 
discussed here have not yet found widespread clinical application, and are for the most 
part still in developmental stages. Much evidence, however, points to their potential 
usefulness, not only in the area of bone disease, but in other internal processes as well. 
TGFß and bFGF, for example, are involved in periosteal healing, which suggests they 
may play a role in the treatment of non-unions, bone-graft enhancement and bone-
lengthening by callous distraction 72. PDGF has been implicated in wound healing, 
scleroderma and atherosclerosis, and may be useful in the treatment of poorly healing 
diabetic ulcers 173. IGF-I has been shown to enhance the healing of experimental defects 
in skull and diaphyseal bone in rats 174. Other possibilities involve the treatment of bone-
wasting disease such as osteoporosis.  
 
Generally, the rationale behind the local and/or systemic therapeutic use of growth 
factors is based on the simple fact that they stimulate bone cell proliferation and 
differentiation in an autocrine and paracrine manner 14, information gained via in vitro 
experimentation. This fact, coupled with the common-sense knowledge that autogenous 
graft material is limited, and that growth factors are compatible and effective in vivo, 
supports continued research in this field. The safe and efficient harnessing of these 
proteins in their various forms could generate a vast potential in new treatment 
modalities. 
 
 
 
 
5.2 Clinical Relevance 
 
One major field which has opened up within the past few years is the area of tissue 
engineering, defined by Reddi (1998) as  “the science of design and manufacture of new 
tissues for the functional restoration of impaired organs and replacement of lost parts 
due to disease or trauma.“ 175. For varying reasons, cell activity or availability may be 
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impaired, such that non-union of large tissue defects occurs. In essence, this therapeutic 
approach to such a problem attempts to mimic the natural process of healing, e.g. an 
exterior source of stem cells inserted in vivo to bridge a large tissue defect. The 
engineering of bone, as is the case with most tissues, requires three basic elements: 1) 
cellular components, which can be introduced from an exterior source, or recruited from 
the body itself; 2) growth and differentiation factors, to direct the stem cells in the 
direction of desired development, and 3) a bioresorbable scaffolding matrix, which not 
only to lends structural support, but also aids in migration and proliferation (Fig. 5.1) 
177,178. When these criteria have been met on the macrocosmic level, the microcosmic 
process of bone formation, (as outlined in Section 1.2.) can begin. 
 
    IDEAL SYNTHETIC BONE GRAFT 
 
      OSTEOINDUCTIVE 
      GROWTH FACTORS 
 
 
 
 
 
   OSTEOCONDUCTIVE   OSTEOPROGENITOR 
    MATRIX        STEM CELLS 
 
Fig.5-1 Elements necessary to achieve optimal bone graft conditions. Taken from Lane et al 
  (1999) 177   
 
5.2.1 Strategies to Determine the Potential Role of Growth Factors in Fracture Healing 
 
What are the current strategies used to introduce these processes into the patient’s 
body? The primary goal in treating any fracture is the rapid induction of a stable callus, 
and previous attempts to replace bone with matrix-based implants (e.g. hydroxyapatite 
ceramics), have met with limited success owing to their lack of osteoinductive activity. 
Present trends are seeking ways to effectively apply biochemical methods, i.e. the 
introduction of exogenous osteoinductive components as a technique of bone 
engineering:  
 
1) Factor-based therapies -  provide direct osteoinductive stimuli by introducing growth 
and differentiation factors into the bone defect via a vehicle, such as demineralised 
bone matrix, loaded with purified or recombinant growth factors 176. The logic behind 
such an approach is to increase the number and mitotic rate of reparative cells at the 
fracture.  
One such study used hyaluronan, a natural glycosaminoglycan polymenantr found in 
the extracellular matrix of most tissue, in the form of a viscous gel to carry 
recombinant bFGF into fresh fractures of animal fibulae. Following a single 
application of 20, 50 or 200 ng bFGF in a 50 µL hyaluronan gel carrier through a 
small-gauge syringe, Radomsky et al (1998) demonstrated a greater callus size, 
bone volume and osteoblast number and activity in treated rabbit fibular bony 
defects compared to control animals 194. 
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Even though this and other pre-clinical in vivo studies have shown promising results 
in rodent models, this success has been difficult to extend to human subjects. 
Optimal therapeutic dose requirements have been extremely variable, as has the 
optimal delivery vehicle with which to present the growth factor to the bony repair 
site. 
  
2) Cell based therapies -  introduce cells with osteogenic potential directly or indirectly 
to the site requiring augmentation. These approaches are particularly effective in 
patients with compromised tissue bed, e.g. severe trauma, diabetes, post-radiation 
therapy, osteoporosis, for the simple reason that they do not depend on host 
osteoprogenitors to induce site-specific bone formation 176. Joyce et al (1990) 
injected TGF-ß beneath the periostium in rat femoral defects and showed that 
periosteal cells differentiated into chondrocytes, proliferated to form a subperiosteal 
cartilage structure, and finally underwent endochondral maturation to achieve bony 
healing 195. 
 
3) Systemic Administration – of a growth factor via osmotic pump or intravenously has 
been shown to enhance the healing of stable defects in intramembranous bone 184.  
Using an osmotic pump to subcutaneously administration IGF-I to rats with a critical-
size calvarial defect, Thaller et al (1993) that after 14 days of receiving IGF-I, the 
bone gap in the treatment animals had advanced healing compared to control group, 
and had practically closed after 8 weeks 196. The healing enhancement achieved with 
this method appears to be best in stable fractures that require acceleration.  
 
 
Any one of these three strategies could have clinical relevance for the culture techniques 
described in this paper. The concept of ex vivo cell cultivation, combined with bioactive 
factors for subsequent introduction into the defect, opens a further possible treatment 
modality in which bone banks could play a vital role in generating, incubating and storing 
bone tissue. This requires the development of reliable, standardized in vitro cultivation 
methods to guarantee the safe acquisition, expansion and harvest of mesenchymal stem 
cell populations.  
  
 
 
 
 
5.3 Cell Culture Considerations  
 
It has been the purpose of this paper to describe the methods and results of in vitro cell 
culture, and to point out the clinical relevance of continued laboratory research. What 
future directions need to be considered?   
 
Generally, future cell-culture considerations need to address the following: 
 
1) More precise determination of the mechanisms / differences between various 
osteoinductive factors and the role of combined simultaneous or sequential delivery 
of multiple factors 178; 
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2) a better understanding of the temporal distribution of these factors during bone repair 
178; 
 
3) the effect of spatial limitations and lifespan in cell-to-cell interaction; 
 
4) the critical dependence of growth factor effects on dose and mode of delivery  176. 
 
 
It must be conceded that in the 30 years since Urist first described bone morphogenic 
proteins, very little of the subsequent experimentation with growth factors has translated 
into common clinical practice. It is therefore our hope that the pursuance and refinement 
of effective in vitro methods may set the stage for this step to take place. 
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Summary:  
 
 
Goal: Extensive studies have shown that undifferentiated cellular components of human 
bone marow are involved in the formation and renewal of bone tissue (osteogenic 
cascade). In this study, human mesenchymal stem cells were stimulated by a variety of 
physiological growth factors in vitro to assess their influence on differentiation to the 
osteoblastic phenotype. Thus human marrow could be used as a malleable basic 
element in bone engineering. 
 
Methods: Progenitor cells were aspirated from human marrow, isolated and cultivated. 
One of the following growth factors was added for a time period of 31 days: : bFGF, IGF-
I, PDGF-BB or TGF-ß1, in 2 different concentrations respectively (1 and 10 µg/mL). 
Every three days the cultures were examined for signs of growth (cell layer thickness, 
cell morphology, calcium content as measured by von Kossa stain, development of bone 
nodules. Further, the osteoblastic-specific markers Osteocalcin (OC) and Procollagen 1 
(PC-1) were biochemically measured via ELISA. 
 
Results:  Depending on the respective growth factor, either a suppressive or stimulatory 
effect was observed. In particular,  the addition of TGF-ß1 induced a concentration-
dependant increase in nodule formation with simultaneous suppression of layer 
formation. BFGF by contrast did not increase nodule formation but rather the formation 
of adipocytes. The PDGF-BB and IGF-I groups were also not associated with increased 
nodule formation compared to the control groups. In all groups, a corresponding 
increase or decrease in osteogenic markers (OC, PC-1) was observed during nodule 
stimulation or suppression, respectively. 
 
Summary:  Our study clearly showed a stimulatory or suppressive effect of each of the 
respective growth factors. In particular the addition of TGF-ß1 directed the differentiation 
of mesenchymal stem cells of human bone marrow toward the osteoblastic phenotype. 
The formation and obtaining of bone marrow is a relatively quick and uncomplicated 
procedure; it would seem to be an optimal resource to serve as a basic element in bone 
engineering. However, further research in the area of the osteogenic cascade is 
necessary if the extracorporal production of bone tissue is to be attained. 
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Zusammenfassung: 
 
Ziel:  Umfangreiche Studien haben gezeigt, dass undifferenzierte zelluläre Komponenten 
aus Knochenmark an der Bildung und Erneuerung des Knochengewebes (die 
sogenannte osteogene Kaskade) beteiligt sind. In dieser Studie wurden menschliche 
mesenchymale Stammzellen durch verschiedene physiologische Wachstumsfaktoren in 
Kulturflaschen stimuliert, um ihre Fähigkeit zu prüfen, dadurch in den osteoblastischen 
Phenotypen zu differenzieren. Menschliches Knochenmark wäre somit als steuerbares 
Grundelement des „Knochenengineerings“ zu gebrauchen. 
 
Methode:  Stammzellen wurden von menschlichem Knochenmark aspiriert, isoliert und 
kultiviert. Einer der folgenden Wachstumsfaktoren wurde den Knochenkulturflaschen für 
einen Zeitraum von 31 Tagen hinzugefügt: bFGF, IGF-I, PDGF-BB oder TGF-ß1, jeweils 
in 2 verschiedenen Konzentrationen (1und 10 µg/mL). Alle 3 Tage wurden die Kulturen 
auf Wachstumkriterien (Bodenschichtbildung, Zellmorphologie, Kalziumgehalt durch von 
Kossa-Färbung, Entstehung von  Knochenknötchen, sogenannten „bone nodules“) 
untersucht. Weiterhin wurden osteoblastenspezifische  Marker wie Osteocalcin (OC) und 
Procollagen 1 (PC-1) biochemisch mittels ELISA gemessen. 
 
Ergebnisse:  Je nach Wachstumsfaktor wurden entweder stimulierende oder 
supprimierende Effekte beobachtet. Insbesondere die Anwendung von TGF-B1 rief eine 
konzentrationsabhängig Zunahme der Nodule-Bildung mit gleichzeitiger Suppression der 
Bodenschichtbildung hervor. Durch bFGF hingegen wurde Nodule-Wachstum nicht 
gefördert, vielmehr stimulierte es die Entstehung von Adipozyten (Fettzellen). Die PDGF-
BB oder IGF-I Kulturen zeigten ebenfalls weniger Nodule- Wachstum als die 
Kontrollgruppen. Insgesamt wurde eine entsprechende Korrelation der 
Knochensynthesemarker (Osteolcalcin, Procollagen-1) beobachtet, d.h. Erhöhung bzw. 
Senkung der Markerspiegel bei Noduleproliferation bzw. Suppression. 
 
Zusammenfassung: Unsere Ergebnisse zeigten eine eindeutig stimulierende bzw. 
supprimierende Wirkung der jeweiligen Wachstumfaktoren. Vorzugsweise durch die 
Zugabe von TGF-ß1 konnte die Differenzierung von Stammzellen einer Kultur 
menschlichen Knochenmarks zugunsten osteoblasten-ähnlichen Endzellen beeinflusst 
werden.  
Die Bildung und Gewinnung von Knochenmark ist relativ schnell und komplikationslos zu 
bewerkstelligen; es scheint daher eine optimale Ressource, um als Grundelement des 
Knochenengineerings zu dienen. Dennoch bedarf es weiterer Forschung auf dem Gebiet 
der Knochendifferenzierungskaskade, um letztendlich vollendetes Knochengewebe 
herstellen zu können. 
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